BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raimondo G, Allain J, Brunetto MR, Buendia M, Chen D, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky J, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. Journal of Hepatology 2008;49:652-7. [DOI: 10.1016/j.jhep.2008.07.014] [Cited by in Crossref: 513] [Cited by in F6Publishing: 504] [Article Influence: 39.5] [Reference Citation Analysis]
Number Citing Articles
1 Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268-1275. [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
2 Lin KT, Chang CL, Tsai MH, Lin KS, Saldanha J, Hung CM. Detection and identification of occult HBV in blood donors in Taiwan using a commercial, multiplex, multi-dye nucleic acid amplification technology screening test. Vox Sang. 2014;106:103-110. [PMID: 23909571 DOI: 10.1111/vox.12075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
3 Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57:720-729. [PMID: 22634131 DOI: 10.1016/j.jhep.2012.05.009] [Cited by in Crossref: 113] [Cited by in F6Publishing: 117] [Article Influence: 12.6] [Reference Citation Analysis]
4 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 10.1] [Reference Citation Analysis]
5 Tajik Z, Bokharaei-Salim F, Ghorbani S, Keyvani H, Esghaei M, Monavari SH, Ataei-Pirkooh A, Garshasbi S, Donyavi T, Fakhim A. Detection of HBV genome in the plasma and peripheral blood mononuclear cells of Iranian HBsAg negative patients with HIV infection: occult HBV infection. Arch Virol 2018;163:1559-66. [PMID: 29476259 DOI: 10.1007/s00705-018-3740-y] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Bautista-Amorocho H, Castellanos-Domínguez YZ, Rodríguez-Villamizar LA, Velandia-Cruz SA, Becerra-Peña JA, Farfán-García AE. Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance. PLoS One 2014;9:e114272. [PMID: 25462190 DOI: 10.1371/journal.pone.0114272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
8 Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46:125-131. [PMID: 20383209 DOI: 10.1038/bmt.2010.70] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
9 Borzooy Z, Jazayeri SM, Mirshafiey A, Khamseh A, Mahmoudie MK, Azimzadeh P, Geravand B, Boroumand MA, Afshar M, Poortahmasebi V. Identification of occult hepatitis B virus (HBV) infection and viral antigens in healthcare workers who presented low to moderate levels of anti-HBs after HBV vaccination. Germs. 2015;5:134-140. [PMID: 26716102 DOI: 10.11599/germs.2015.1081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Spreafico M, Berzuini A, Foglieni B, Candotti D, Raffaele L, Guarnori I, Colli A, Maldini FF, Allain J, Prati D. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. Journal of Hepatology 2015;63:1068-76. [DOI: 10.1016/j.jhep.2015.06.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
11 Bai F, Yano Y, Fukumoto T, Takebe A, Tanaka M, Kuramitsu K, Anggorowati N, Rinonce HT, Widasari DI, Saito M, Hirano H, Hayakumo T, Seo Y, Azuma T, Ku Y, Hayashi Y. Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol 2013;2013:849290. [PMID: 24455286 DOI: 10.1155/2013/849290] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
12 Bhatia M, Gupta E, Choudhary MC, Jindal A, Sarin SK. Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: A retrospective cohort study. J Lab Physicians 2018;10:304-8. [PMID: 30078967 DOI: 10.4103/JLP.JLP_12_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
14 Coppola N, Onorato L, Iodice V, Starace M, Minichini C, Farella N, Liorre G, Filippini P, Sagnelli E, de Stefano G. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. Oncotarget. 2016;7:62706-62714. [PMID: 27486882 DOI: 10.18632/oncotarget.10909] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
15 Lai A, Sagnelli C, Presti AL, Cella E, Angeletti S, Spoto S, Costantino S, Sagnelli E, Ciccozzi M. What is changed in HBV molecular epidemiology in Italy? J Med Virol. 2018;90:786-795. [PMID: 29315661 DOI: 10.1002/jmv.25027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
16 Willmore J, Ellis E, Etches V, Labrecque L, Osiowy C, Andonov A, McDermaid C, Majury A, Achonu C, Maher M, MacLean B, Levy I. Public health response to a large-scale endoscopy infection control lapse in a nonhospital clinic. Can J Infect Dis Med Microbiol 2015;26:77-84. [PMID: 26015789 DOI: 10.1155/2015/160536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, Hong SK, Joo MK, Yeon JE, Park JJ, Kim JS, Bak Y, Byun KS. Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir. Journal of Clinical Gastroenterology 2010;44:653-7. [DOI: 10.1097/mcg.0b013e3181d52946] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
18 Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, Ide T, Ueda J, Noshiro H. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C patients with curative resection for hepatocellular carcinoma. World J Hepatol 2017; 9(35): 1286-1295 [PMID: 29290910 DOI: 10.4254/wjh.v9.i35.1286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon 2012;12:e6126. [PMID: 23087749 DOI: 10.5812/hepatmon.6126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
20 Guimarães MNC, Facincani T, Santos SDSD. Hepatitis B status in hemodialysis patients. Arq Gastroenterol 2017;54:356-8. [DOI: 10.1590/s0004-2803.201700000-34] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 23.0] [Reference Citation Analysis]
22 Kwan KW, Lim TR, Kumar R, Krishnamoorthy TL. Understanding the hepatitis B core positive liver donor. Singapore Med J. 2018;. [PMID: 30182132 DOI: 10.11622/smedj.2018104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Gencay M, Hübner K, Gohl P, Seffner A, Weizenegger M, Neofytos D, Batrla R, Woeste A, Kim HS, Westergaard G, Reinsch C, Brill E, Thu Thuy PT, Hoang BH, Sonderup M, Spearman CW, Pabinger S, Gautier J, Brancaccio G, Fasano M, Santantonio T, Gaeta GB, Nauck M, Kaminski WE. Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population. PLoS One 2017;12:e0172101. [PMID: 28472040 DOI: 10.1371/journal.pone.0172101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
24 Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis. 2010;42 Suppl 3:S215-S222. [PMID: 20547306 DOI: 10.1016/s1590-8658(10)60508-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
25 Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, Battisti A, Ricciardi A, Pollicita M, Bianchi A, Picardi A, Cudillo L, Cerretti R, De Angelis G, Cantonetti M, Andreoni M, Perno CF, Arcese W, Svicher V, Sarmati L. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 2016;22:946.e1-8. [PMID: 27475741 DOI: 10.1016/j.cmi.2016.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
26 Bes M, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol. 2012;56:765-774. [PMID: 22173156 DOI: 10.1016/j.jhep.2011.11.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
27 Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola A, Di Grazia C, Dominietto A, Varaldo R, Ghiso A, Bacigalupo A, Viscoli C. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clinical Microbiology and Infection 2014;20:O694-701. [DOI: 10.1111/1469-0691.12611] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
28 Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother. 2010;11:919-928. [PMID: 20166841 DOI: 10.1517/14656561003637659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
29 Chen J, Liu Y, Zhao J, Xu Z, Chen R, Si L, Lu S, Li X, Wang S, Zhang K, Li J, Han J, Xu D. Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection. PLoS One. 2016;11:e0155654. [PMID: 27182775 DOI: 10.1371/journal.pone.0155654] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
30 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. [PMID: 29035003 DOI: 10.1111/apt.14376] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 20.0] [Reference Citation Analysis]
31 Malagnino V, Fofana DB, Lacombe K, Gozlan J. Occult Hepatitis B Virus Infection: An Old Entity With Novel Clinical Involvements. Open Forum Infect Dis 2018;5:ofy227. [PMID: 30324127 DOI: 10.1093/ofid/ofy227] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
32 Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. J Viral Hepat 2020;27:4-12. [PMID: 31325404 DOI: 10.1111/jvh.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
33 He Q, Song X, Huang Y, Huang W, Ye B, Luo H, Luo H, Wu L, Wang Z, Chen W, Zhang L. Dexamethasone Stimulates Hepatitis B Virus (HBV) Replication Through Autophagy. Med Sci Monit 2018;24:4617-24. [PMID: 29972684 DOI: 10.12659/MSM.906250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
34 Wang ZL, Gao S, Li XY, Sun FK, Li F, Fan YC, Wang K. Demethylation of tumor necrosis factor-α converting enzyme promoter associated with high hepatitis B e antigen level in chronic hepatitis B. World J Gastroenterol 2015; 21(27): 8382-8388 [PMID: 26217090 DOI: 10.3748/wjg.v21.i27.8382] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Ocana S, Casas ML, Buhigas I, Lledo JL. Diagnostic strategy for occult hepatitis B virus infection. World J Gastroenterol 2011; 17(12): 1553-1557 [PMID: 21472120 DOI: 10.3748/wjg.v17.i12.1553] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
36 Zinserling VA, Esaulenko EV, Karev VE, Bubochkin AB, Sukhoruk AA, Shibaeva EO, Ponyatishina MV. [Clinical and morphological correlations in occult hepatitis B]. Arkh Patol 2017;79:8-13. [PMID: 29265072 DOI: 10.17116/patol20177968-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
37 Jepkemei KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, McKinnon LR, Andonov A, Oyugi J, Kimani J, Gachara G, Songok EM, Osiowy C. Characterization of occult hepatitis B in high-risk populations in Kenya. PLoS One 2020;15:e0233727. [PMID: 32463824 DOI: 10.1371/journal.pone.0233727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Yooda AP, Soubeiga ST, Nebie KY, Diarra B, Sawadogo S, Ouattara AK, Obiri-Yeboah D, Yonli AT, Tao I, Sorgho PA, Dahourou H, Simpore J. Impact of Multiplex PCR in Reducing the Risk of Residual Transfusion-Transmitted Human Immunodeficiency and Hepatitis B and C Viruses in Burkina Faso. Mediterr J Hematol Infect Dis 2018;10:e2018041. [PMID: 30002797 DOI: 10.4084/MJHID.2018.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Hatazawa Y, Yano Y, Okada R, Tanahashi T, Hayashi H, Hirano H, Minami A, Kawano Y, Tanaka M, Fukumoto T, Murakami Y, Yoshida M, Hayashi Y. Quasispecies variant of pre-S/S gene in HBV-related hepatocellular carcinoma with HBs antigen positive and occult infection. Infect Agent Cancer 2018;13:7. [PMID: 29434654 DOI: 10.1186/s13027-018-0179-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
40 Candotti D, Laperche S. Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures? Front Med (Lausanne) 2018;5:29. [PMID: 29515997 DOI: 10.3389/fmed.2018.00029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
41 Pollicino T, Vegetti A, Saitta C, Ferrara F, Corradini E, Raffa G, Pietrangelo A, Raimondo G. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol. 2013;58:190-193. [PMID: 22989571 DOI: 10.1016/j.jhep.2012.09.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
42 Said ZN, Sayed MHE, Salama II, Aboel-Magd EK, Mahmoud MH, Setouhy ME, Mouftah F, Azzab MB, Goubran H, Bassili A, Esmat GE. Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol 2013; 5(2): 64-73 [PMID: 23646231 DOI: 10.4254/wjh.v5.i2.64] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
43 Ba Alawi F, Robertson PW, LePage AK, Jayamaha J, Baleriola C, Rawlinson WD. The reliability of HBV core antibody in serological screening for hepatitis B virus. Pathology 2013;45:501-5. [PMID: 23842045 DOI: 10.1097/PAT.0b013e3283631cf9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
44 Szymanek-Pasternak A, Simon KA, Serafińska S, Janocha-Litwin J, Pazgan-Simon M, Madej G. The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin. Clin Exp Hepatol 2016;2:155-60. [PMID: 28856281 DOI: 10.5114/ceh.2016.63873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
45 Caviglia GP, Abate ML, Tandoi F, Ciancio A, Amoroso A, Salizzoni M, Saracco GM, Rizzetto M, Romagnoli R, Smedile A. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J Hepatol. 2018;69:301-307. [PMID: 29621551 DOI: 10.1016/j.jhep.2018.03.021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 19.3] [Reference Citation Analysis]
46 Lai MW, Lin TY, Liang KH, Lin WR, Yeh CT. Hepatitis B viremia in completely immunized individuals negative for anti-hepatitis B core antibody. Medicine (Baltimore) 2016;95:e5625. [PMID: 27930595 DOI: 10.1097/MD.0000000000005625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
47 Ozaslan E, Purnak T. Is it a case of transfusion-transmitted acute HBV or reactivation of occult hepatitis B virus infection? Transfusion Medicine 2010;20:275-275. [DOI: 10.1111/j.1365-3148.2010.01014.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
48 Kim DH, Kim SB. Hepatic Failure by Spontaneous Reactivation of Hepatitis B Virus without a Trigger Factor in a Patient with Anti-HBs. Case Rep Gastroenterol 2018;12:286-91. [PMID: 30022917 DOI: 10.1159/000490099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
50 Midorikawa Y, Takayama T, Nakayama H, Higaki T, Moriguchi M, Moriya K, Kanda T, Matsuoka S, Moriyama M. Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. BMC Gastroenterol 2019;19:147. [PMID: 31426746 DOI: 10.1186/s12876-019-1069-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:434-442. [PMID: 21374690 DOI: 10.1002/hep.24257] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
52 Caviglia GP, Abate ML, Manzini P, Danielle F, Ciancio A, Rosso C, Olivero A, Pellicano R, Touscoz GA, Smedile A, Rizzetto M. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. Hepat Mon 2012;12:e7292. [PMID: 23300497 DOI: 10.5812/hepatmon.7292] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
53 Darmawan E, Turyadi KE, Nursanty NK, Thedja MD, Muljono DH. Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. J Med Virol. 2015;87:199-207. [PMID: 25521058 DOI: 10.1002/jmv.24045] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
54 Saha D, Pal A, Sarkar N, Das D, Blackard JT, Guha SK, Saha B, Chakravarty R. Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India. PLoS One. 2017;12:e0179035. [PMID: 28591184 DOI: 10.1371/journal.pone.0179035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Chancharoenthana W, Leelahavanichkul A, Udomkarnjananun S, Wattanatorn S, Avihingsanon Y, Praditpornsilpa K, Tungsanga K, Eiam-Ong S, Townamchai N. Durability of Antibody Response Against the Hepatitis B Virus in Kidney Transplant Recipients: A Proposed Immunization Guideline From a 3-Year Follow-up Clinical Study. Open Forum Infect Dis 2019;6:ofy342. [PMID: 30697573 DOI: 10.1093/ofid/ofy342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Ganova-Raeva L, Punkova L, Campo DS, Dimitrova Z, Skums P, Vu NH, Dat do T, Dalton HR, Khudyakov Y. Cryptic Hepatitis B and E in Patients With Acute Hepatitis of Unknown Etiology. J Infect Dis 2015;212:1962-9. [PMID: 26155829 DOI: 10.1093/infdis/jiv315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
57 Silva JL, De Deus DM, Moreira RC, de Morais CN, Coêlho MR. The relationship between hepatitis B virus (HBV) load and levels of transforming growth factor beta 1 (TGF-β1) and soluble Fas (sFas) in human immunodeficiency virus patients with occult HBV infection. Arch Virol 2015;160:1801-4. [PMID: 25990938 DOI: 10.1007/s00705-015-2445-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Akinniyi OG, Adetunji SO, Alawode-Obabiyi LA, Japhet MO, Donbraye E. Serological patterns of hepatitis B virus infection among people living with HIV in Ibadan, Nigeria. J Immunoassay Immunochem 2021;42:444-52. [PMID: 33750262 DOI: 10.1080/15321819.2021.1895218] [Reference Citation Analysis]
59 Baghbanian M, Halvani M, Roghani HS, Lotfi MH, Yazdi MF, Vahedian-Ardakani HA. PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT. Arq Gastroenterol 2016;53:175-9. [PMID: 27438423 DOI: 10.1590/S0004-28032016000300010] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Laohapand C, Arromdee E, Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int. 2015;9:202-208. [PMID: 25788188 DOI: 10.1007/s12072-014-9597-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
61 Ostankova YV, Semenov AV, Totolian AA. [The quantitative determination method of covalently closed circular DNA HBV in puncture biopsy specimens of the liver.]. Klin Lab Diagn 2019;64:565-70. [PMID: 31610110 DOI: 10.18821/0869-2084-2019-64-9-565-570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 7.7] [Reference Citation Analysis]
63 Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
64 Diarra B, Yonli AT, Sorgho PA, Compaore TR, Ouattara AK, Zongo WA, Tao I, Traore L, Soubeiga ST, Djigma FW. Occult Hepatitis B Virus Infection and Associated Genotypes among HBsAg-negative Subjects in Burkina Faso. Mediterr J Hematol Infect Dis. 2018;10:e2018007. [PMID: 29326804 DOI: 10.4084/mjhid.2018.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
65 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
66 Martín Hidalgo-Barquero MV, Ruiz-Calero Cendrero RM, Cancho Castellano B, Cid Parra MC, Galán González J. Chemotherapy and occult reactivation of HBV in hemodialysis patients. Nefrologia (Engl Ed) 2020;40:565-6. [PMID: 31627973 DOI: 10.1016/j.nefro.2019.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Ozaslan E, Demirezer A, Yavuz B. Occult hepatitis B virus infection in Turkish healthy individuals. Eur J Gastroenterol Hepatol 2009;21:1436-7. [PMID: 19907228 DOI: 10.1097/10.1097/MEG.0b013e328321b124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
68 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology. 2015;61:1183-1191. [PMID: 25501911 DOI: 10.1002/hep.27650] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
70 Escobedo-Melendez G, Panduro A, Fierro NA, Roman S. High prevalence of occult hepatitis B virus genotype H infection among children with clinical hepatitis in west Mexico. Mem Inst Oswaldo Cruz 2014;109:728-37. [PMID: 25099333 DOI: 10.1590/0074-0276140058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
71 Madhavan A, Sachu A, Balakrishnan AK, Balakrishnan S, Vasudevapanicker J. Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B. J Lab Physicians 2021;13:1-5. [PMID: 34054234 DOI: 10.1055/s-0041-1723046] [Reference Citation Analysis]
72 Akinbami A, Badiru M, Uche E, Onyekwere C, Ismail K, Olowoselu O, Oluwole E, Suleiman A, Augustine B, Olaosebikan H. The Prevalence of Occult Hepatitis B Infection among Blood Donors in Lagos, Nigeria. Niger Med J 2019;60:22-6. [PMID: 31413431 DOI: 10.4103/nmj.NMJ_29_19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Ostankova YV, Semenov AV, Totolian AA. [Hepatitis B virus identification in a blood plasma at a low viral load.]. Klin Lab Diagn 2019;64:635-40. [PMID: 31742959 DOI: 10.18821/0869-2084-2019-64-10-635-640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
74 Voican C, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, Chaussade S, Pol S, Coriat R. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Annals of Oncology 2016;27:2172-83. [DOI: 10.1093/annonc/mdw414] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
75 Fontenele AMM, Gainer JBF, da Silva e Silva DV, Cruz Santos MD, Salgado JV, Salgado Filho N, Ferreira ASP. Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil: Occult hepatitis B on hemodialysis. Hemodial Int 2015;19:353-9. [DOI: 10.1111/hdi.12285] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
76 Blanco S, Balangero MC, Valle MC, Montini OL, Carrizo LH, Gallego SV. Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections. Transfusion 2017;57:816-22. [PMID: 27917495 DOI: 10.1111/trf.13946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
77 Wu SS, Shan QY, Xie WX, Chen B, Huang Y, Guo Y, Xie XY, Lu MD, Peng BG, Kuang M, Shen SL, Wang W. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol 2020;22:401-10. [PMID: 31172445 DOI: 10.1007/s12094-019-02141-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Hao Q, Wang Q, Qian H, Jiang J, Liu X, Xia W. Identification and functional characterization of miR-451a as a novel plasma-based biomarker for occult hepatitis B virus infection. Microb Pathog 2021;161:105233. [PMID: 34626767 DOI: 10.1016/j.micpath.2021.105233] [Reference Citation Analysis]
80 Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’armiento M, Borgia G, Sagnelli E. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Annals of Hepatology 2014;13:20-6. [DOI: 10.1016/s1665-2681(19)30900-7] [Cited by in Crossref: 20] [Article Influence: 2.9] [Reference Citation Analysis]
81 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
82 Goel A, Eapen CE, Danda D. Infliximab and occult Hepatitis B infection: to treat or not to treat? Int J Rheum Dis 2013;16:377-8. [DOI: 10.1111/1756-185x.12184] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Nna E, Mbamalu C, Ekejindu I. Occult hepatitis B viral infection among blood donors in South-Eastern Nigeria. Pathog Glob Health 2014;108:223-8. [PMID: 24995918 DOI: 10.1179/2047773214Y.0000000144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
84 Morales-Romero J, Vargas G, García-Román R. Occult HBV infection: a faceless enemy in liver cancer development. Viruses. 2014;6:1590-1611. [PMID: 24717680 DOI: 10.3390/v6041590] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
85 Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN; Liver Match Investigators. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013;58:715-723. [PMID: 23201239 DOI: 10.1016/j.jhep.2012.11.025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
86 Michalak TI. Diverse Virus and Host-Dependent Mechanisms Influence the Systemic and Intrahepatic Immune Responses in the Woodchuck Model of Hepatitis B. Front Immunol. 2020;11:853. [PMID: 32536912 DOI: 10.3389/fimmu.2020.00853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
87 Liu Y, Wen J, Chen J, Xu C, Hu Y, Zhou YH. Rare detection of occult hepatitis B virus infection in children of mothers with positive hepatitis B surface antigen. PLoS One 2014;9:e112803. [PMID: 25383543 DOI: 10.1371/journal.pone.0112803] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
88 Zhu HL, Li X, Li J, Zhang ZH. Genetic variation of occult hepatitis B virus infection. World J Gastroenterol 2016; 22(13): 3531-3546 [PMID: 27053845 DOI: 10.3748/wjg.v22.i13.3531] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 8.6] [Reference Citation Analysis]
89 Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transfus. 2009;7:174-182. [PMID: 19657480 DOI: 10.2450/2008.0062-08] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
90 Dickens C, Kew MC, Purcell RH, Kramvis A. Occult hepatitis B virus infection in chacma baboons, South Africa. Emerg Infect Dis. 2013;19:598-605. [PMID: 23631817 DOI: 10.3201/eid1904.121107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
91 Jutavijittum P, Andernach IE, Yousukh A, Samountry B, Samountry K, Thammavong T, Keokhamphue J, Toriyama K, Muller CP. Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang 2014;106:31-7. [PMID: 23931585 DOI: 10.1111/vox.12073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
92 Choudhuri G, Gupta V, Negi TS, Ojha R. Potential Implications of Detecting HBsAg in Asymptomatic People in an Endemic Community Through Medical Camps. J Clin Exp Hepatol 2019;9:43-9. [PMID: 30765938 DOI: 10.1016/j.jceh.2018.02.005] [Reference Citation Analysis]
93 Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916-924. [PMID: 19885908 DOI: 10.1002/ibd.21147] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
94 Harvala H, Reynolds C, Gibney Z, Derrick J, Ijaz S, Davison KL, Brailsford S. Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety? Transfusion 2021;61:2402-13. [PMID: 34114670 DOI: 10.1111/trf.16543] [Reference Citation Analysis]
95 Allain J, Opare-sem O. Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol 2016;13:643-53. [DOI: 10.1038/nrgastro.2016.138] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
96 Mondal RK, Khatun M, Banerjee P, Ghosh A, Sarkar S, Santra A, Das K, Chowdhury A, Banerjee S, Datta S. Synergistic impact of mutations in Hepatitis B Virus genome contribute to its occult phenotype in chronic Hepatitis C Virus carriers. Sci Rep 2017;7:9653. [PMID: 28852072 DOI: 10.1038/s41598-017-09965-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
97 Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52. [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 123] [Article Influence: 14.6] [Reference Citation Analysis]
98 Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21:153-162. [PMID: 24438677 DOI: 10.1111/jvh.12222] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
99 Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat 2018;25:72-9. [PMID: 28703895 DOI: 10.1111/jvh.12754] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
100 Lazarevic I. Clinical implications of hepatitis B virus mutations: Recent advances. World J Gastroenterol 2014; 20(24): 7653-7664 [PMID: 24976703 DOI: 10.3748/wjg.v20.i24.7653] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 81] [Article Influence: 11.7] [Reference Citation Analysis]
101 Vargas JI, Jensen D, Sarmiento V, Peirano F, Acuña P, Fuster F, Soto S, Ahumada R, Huilcaman M, Bruna M, Jensen W, Fuster F. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile. J Med Virol 2016;88:639-46. [PMID: 26381185 DOI: 10.1002/jmv.24384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
102 Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5951-5961 [PMID: 24876718 DOI: 10.3748/wjg.v20.i20.5951] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
103 Wang T, Shen C, Chen L, Liu S, Ji Y. Association of human leukocyte antigen polymorphisms with occult hepatitis B virus infection in a Shaanxi Han population. J Gene Med 2017;19. [PMID: 28940887 DOI: 10.1002/jgm.2987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
105 Trinks J, Sugiyama M, Tanaka Y, Kurbanov F, Benetucci J, Giménez E, Weissenbacher MC, Mizokami M, Oubiña JR. In vitro replication competence of a hepatitis B genotype D/A recombinant virus: dissimilar biological behaviour regarding its parental genotypes. Journal of General Virology 2013;94:2724-8. [DOI: 10.1099/vir.0.053595-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Bal T, Onlen Y. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy. Arab J Gastroenterol 2018;19:33-6. [PMID: 29503077 DOI: 10.1016/j.ajg.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Emara MH, El-Gammal NE, Mohamed LA, Bahgat MM. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. Virol J. 2010;7:324. [PMID: 21083926 DOI: 10.1186/1743-422x-7-324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
108 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
109 Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine M. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. J Infect Dis 2021:jiab327. [PMID: 34160616 DOI: 10.1093/infdis/jiab327] [Reference Citation Analysis]
110 Zhang M, Wu R, Jiang J, Minuk GY, Niu J. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. Alcohol. 2013;47:553-558. [PMID: 24041840 DOI: 10.1016/j.alcohol.2013.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
111 Coffin CS, Mulrooney-Cousins PM, Michalak TI. Hepadnaviral Lymphotropism and Its Relevance to HBV Persistence and Pathogenesis. Front Microbiol 2021;12:695384. [PMID: 34421849 DOI: 10.3389/fmicb.2021.695384] [Reference Citation Analysis]
112 Ghaziasadi A, Fakhari Z, Aghcheli B, Poortahmasebi V, Farahmand M, Norouzi M, Ghalichi L, Soleimani A, Hedayat Yaghoobi M, Ravanshad M, Jazayeri SM. High prevalence of occult hepatitis B infection (OBI) among healthy children and their parents in Alborz province, Iran; Vertical OBI, myth or truth? Liver Int 2020;40:92-100. [PMID: 31518482 DOI: 10.1111/liv.14252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Gao S, Fan Y, Zhao J, Sun F, Han J, Zhao Z, Wang K. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase ≤2 upper limit of normal. Liver Int 2014;34:e229-37. [DOI: 10.1111/liv.12344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
114 Calvaruso V, Craxì A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol 2017;67:898-901. [PMID: 28864279 DOI: 10.1016/j.jhep.2017.08.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
115 Singh L, Bell TG, Yousif M, Kramvis A. Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults. J Med Virol 2019;91:758-64. [PMID: 30515847 DOI: 10.1002/jmv.25375] [Reference Citation Analysis]
116 Moraes TC, Fiaccadori FS, Souza M, Almeida TN, Cunha Mdos P, Castro Íde A, Cardoso Dd. Hepatitis B virus infection among institutionalized mentally ill patients in Brazil. Braz J Infect Dis 2015;19:643-7. [PMID: 26361836 DOI: 10.1016/j.bjid.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
117 Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion. 2012;52:440-446. [PMID: 21810101 DOI: 10.1111/j.1537-2995.2011.03283.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
118 El Chaar M, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology. 2010;52:1600-1610. [PMID: 20815025 DOI: 10.1002/hep.23886] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
119 Serikova EN, Semenov AV, Ostankova YV, Totolian AA. Method for detecting hepatitis B virus in blood plasma at low viral load using real-time PCR. Klin Lab Diagn 2021;66:59-64. [PMID: 33567175 DOI: 10.18821/0869-2084-2021-66-1-59-64] [Reference Citation Analysis]
120 Araújo-Mariz C, Lopes EP, Ximenes RA, Lacerda HR, Miranda-Filho DB, Montarroyos UR, Barreto S, Salustiano DM, Albuquerque MF. Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis. J Med Virol. 2016;88:996-1002. [PMID: 26580855 DOI: 10.1002/jmv.24432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292 [PMID: 24868322 DOI: 10.4254/wjh.v6.i5.284] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
122 Velati C, Fomiatti L, Baruffi L, Piccinini V, Prati D, Reina A, Lobbiani A, Zanetti A, Romanò L. Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group. Blood Transfus 2011;9:455-61. [PMID: 21839007 DOI: 10.2450/2011.0014-11] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
123 Puoti C. How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice? Eur J Intern Med 2013;24:100-3. [PMID: 23167981 DOI: 10.1016/j.ejim.2012.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
124 Saitta C, Lanza M, Bertuccio A, Lazzara S, Navarra G, Raimondo G, Pollicino T. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection. Cancer Genet 2015;208:513-6. [PMID: 26341700 DOI: 10.1016/j.cancergen.2015.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
125 Kar P, Mishra S. Management of hepatitis B during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:301-10. [DOI: 10.1517/14656566.2016.1118051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
126 Yang YT, Huang AL, Zhao Y. The prevalence of hepatitis B core antibody in vaccinated Chinese children: A hospital-based study. Vaccine 2019;37:458-63. [PMID: 30527659 DOI: 10.1016/j.vaccine.2018.11.067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
127 Hernandez BY, Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:2016-23. [PMID: 23983238 DOI: 10.1158/1055-9965.EPI-13-0397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
128 Anderson M, Choga WT, Moyo S, Bell TG, Mbangiwa T, Phinius BB, Bhebhe L, Sebunya TK, Lockman S, Marlink R, Kramvis A, Essex M, Musonda RM, Blackard JT, Gaseitsiwe S. Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana. Genes (Basel) 2018;9:E453. [PMID: 30205537 DOI: 10.3390/genes9090453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
129 Yeh C, Lai M. Eliminating hepatitis B virus through neonatal vaccination: Can we make it? Journal of Hepatology 2012;57:484-5. [DOI: 10.1016/j.jhep.2012.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
130 Stasi C, Silvestri C, Voller F. Emerging Trends in Epidemiology of Hepatitis B Virus Infection. J Clin Transl Hepatol 2017;5:272-6. [PMID: 28936408 DOI: 10.14218/JCTH.2017.00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
131 Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, Enriquez-Navarro K, Alvarez-Muñoz MT, Lira R. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance. World J Hepatol 2015; 7(2): 253-260 [PMID: 25729480 DOI: 10.4254/wjh.v7.i2.253] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
132 Tandoi F, Caviglia GP, Pittaluga F, Abate ML, Smedile A, Romagnoli R, Salizzoni M. Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. Digestive and Liver Disease 2014;46:1020-4. [DOI: 10.1016/j.dld.2014.07.172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
133 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
134 Kamitsukasa H, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, Okamoto H. Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection. J Med Virol 2015;87:589-600. [PMID: 25612181 DOI: 10.1002/jmv.24115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
135 Dessordi R, Santana RC, Navarro AM. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Rev Soc Bras Med Trop 2019;52:e20180441. [PMID: 31596347 DOI: 10.1590/0037-8682-0441-2018] [Reference Citation Analysis]
136 Anderson M, Choga WT, Moyo S, Bell TG, Mbangiwa T, Phinius BB, Bhebhe L, Sebunya TK, Makhema J, Marlink R, Kramvis A, Essex M, Musonda RM, Blackard JT, Gaseitsiwe S. In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm. Genes (Basel) 2018;9:E420. [PMID: 30134551 DOI: 10.3390/genes9090420] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
137 Nielsen US, Thomsen RW, Cowan S, Larsen CS, Petersen E. Predictors of travel-related hepatitis A and B among native adult Danes: A nationwide case-control study. Journal of Infection 2012;64:399-408. [DOI: 10.1016/j.jinf.2011.12.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
138 Hao QQ, Wang QH, Xia W, Qian HZ. Circulating miRNA expression profile and bioinformatics analysis in patients with occult hepatitis B virus infection. J Med Virol 2020;92:191-200. [PMID: 31513283 DOI: 10.1002/jmv.25594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M, Di Costanzo G, Starace M, Pasquale G, Cacciapuoti C, Petruzziello A. HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315-317. [PMID: 23856167 DOI: 10.1016/j.jcv.2013.06.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
140 Pisaturo M, Onorato L, Russo A, Coppola N. Prevalence of occult HBV infection in Western countries. J Med Virol 2020. [PMID: 32275083 DOI: 10.1002/jmv.25867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Apica BS, Seremba E, Rule J, Yuan HJ, Lee WM. High prevalence of occult hepatitis B infection in an African urban population. J Med Virol 2016;88:674-80. [PMID: 26334654 DOI: 10.1002/jmv.24372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
142 Foy MC, Thio CL, Hwang HS, Saulynas M, Hamilton JP, Fine DM, Atta MG. False-negative hepatitis B virus (HBV) surface antigen in a vaccinated dialysis patient with a high level of HBV DNA in the United States. Clin Vaccine Immunol. 2012;19:820-822. [PMID: 22441395 DOI: 10.1128/cvi.05696-11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
143 Rivière L, Ducroux A, Buendia MA. The oncogenic role of hepatitis B virus. Recent Results Cancer Res. 2014;193:59-74. [PMID: 24008293 DOI: 10.1007/978-3-642-38965-8_4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
144 Selmi C, Ceribelli A, Vierling JM. Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis. Semin Immunopathol 2013;35:1-5. [PMID: 23250654 DOI: 10.1007/s00281-012-0359-z] [Reference Citation Analysis]
145 Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6(12): 860-869 [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
146 Wang Z, Zeng J, Li T, Zheng X, Xu X, Ye X, Lu L, Zhu W, Yang B, Allain JP, Li C. Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen, China. BMC Infect Dis 2016;16:498. [PMID: 27647214 DOI: 10.1186/s12879-016-1834-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
147 Zhang K, Liu Y, Chen R, Li Q, Xu Z, Si L, Cheng Y, Yang Y, Chen J, Xu D, Lin S. Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection. J Med Virol. 2018;90:263-270. [PMID: 28876463 DOI: 10.1002/jmv.24936] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
148 Mitsumoto-Kaseida F, Murata M, Takayama K, Toyoda K, Ogawa E, Furusyo N, Hayashi J. Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. J Infect Chemother 2020;26:28-32. [PMID: 31279522 DOI: 10.1016/j.jiac.2019.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Inuzuka T, Ueda Y, Morimura H, Fujii Y, Umeda M, Kou T, Osaki Y, Uemoto S, Chiba T, Marusawa H. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence. J Hepatol. 2014;61:492-501. [PMID: 24798622 DOI: 10.1016/j.jhep.2014.04.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
150 Xiong QF, Zhong YD, Hu ZL, Yang YF. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy. Acta Clin Belg 2015;70:223-5. [PMID: 25510219 DOI: 10.1179/2295333714Y.0000000108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Pisaturo M, Onorato L, Russo A, Chiodini P, Coppola N. An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: A meta-analysis. J Viral Hepat 2020;27:415-27. [PMID: 31834645 DOI: 10.1111/jvh.13248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
152 Ye X, Zhao Y, Li R, Li T, Zheng X, Xiong W, Zeng J, Xu M, Chen L. High Frequency Occult Hepatitis B Virus Infection Detected in Non-Resolved Donations Suggests the Requirement of Anti-HBc Test in Blood Donors in Southern China. Front Immunol 2021;12:699217. [PMID: 34394093 DOI: 10.3389/fimmu.2021.699217] [Reference Citation Analysis]
153 Coffin CS, Terrault NA. Management of patients co-infected with HBV and HCV. Expert Rev Anti Infect Ther 2009;7:549-58. [PMID: 19485795 DOI: 10.1586/eri.09.38] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
155 Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009;1:e2009025. [PMID: 21415959 DOI: 10.4084/mjhid.2009.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
156 Zheng X, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain JP, Li C. Characterization of occult hepatitis B virus infection from blood donors in China. J Clin Microbiol. 2011;49:1730-1737. [PMID: 21411575 DOI: 10.1128/jcm.00145-11] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
157 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
158 Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS One 2021;16:e0244947. [PMID: 33406137 DOI: 10.1371/journal.pone.0244947] [Reference Citation Analysis]
159 Samardžija M, Drenjančević D, Miletić M, Slavulj B, Jukić I, Zibar L, Mihaljević S, Ferenac Kiš M, Samardžija M. THE IMPACT OF POSITIVE ANTI-HBC MARKER ON PERMANENT DEFERRAL OF VOLUNTARY BLOOD DONORS IN EASTERN CROATIA AND ESTIMATION OF OCCULT HEPATITIS B VIRUS INFECTION RATE. Acta Clin Croat 2020;59:126-34. [PMID: 32724283 DOI: 10.20471/acc.2020.59.01.15] [Reference Citation Analysis]
160 Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2011;17:261-267. [PMID: 22310790 DOI: 10.3350/kjhep.2011.17.4.261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
161 Sofian M, Aghakhani A, Izadi N, Banifazl M, Kalantar E, Eslamifar A, Ramezani A. Lack of occult hepatitis B virus infection among blood donors with isolated hepatitis B core antibody living in an HBV low prevalence region of Iran. Int J Infect Dis 2010;14:e308-10. [PMID: 19656713 DOI: 10.1016/j.ijid.2009.05.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
162 Datta S, Chatterjee S, Veer V. Recent advances in molecular diagnostics of hepatitis B virus. World J Gastroenterol 2014; 20(40): 14615-14625 [PMID: 25356025 DOI: 10.3748/wjg.v20.i40.14615] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
163 Martinez MC, Kok CC, Baleriola C, Robertson P, Rawlinson WD. Investigation of occult hepatitis B virus infection in anti-hbc positive patients from a liver clinic. PLoS One. 2015;10:e0117275. [PMID: 25763579 DOI: 10.1371/journal.pone.0117275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
164 Tan HH, Martin P. Management of end-stage liver disease in chronic hepatitis B. Clin Liver Dis. 2010;14:477-493. [PMID: 20638026 DOI: 10.1016/j.cld.2010.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
165 Wen X, Su H, Wang Y, Pu Z, Gao J, Ji Z, Yuan X, Li X, Zhang W, Zhang L, Long Y, Yan Y, Shao Z. Prevalence and natural course of occult hepatitis B virus infection in residents of 2 communities of Wuwei City, Gansu Province, China. J Viral Hepat 2018;25:281-8. [DOI: 10.1111/jvh.12805] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
166 Wang C, Chen G, Lau G. Reply. Clinical Gastroenterology and Hepatology 2017;15:605-6. [DOI: 10.1016/j.cgh.2016.12.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Costa JEF, Morais VMS, Gonçales JP, Medeiros AADP, Barroso H, Compri AP, Fukasawa L, Moreira RC, Coêlho MRCD. Occult hepatitis B virus infection in patients with leprosy. J Med Virol 2019;91:775-80. [PMID: 30512182 DOI: 10.1002/jmv.25374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Velati C. Occult B hepatitis - still a risk for transfusions?: Occult B hepatitis and transfusion. ISBT Science Series 2010;5:73-6. [DOI: 10.1111/j.1751-2824.2010.01398.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 2011;41:711-21. [PMID: 21682827 DOI: 10.1111/j.1872-034X.2011.00818.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
170 Mohraz M, Jafari R, Poortahmasebi V, Sadeghi A, Hajabdolbaghi M, Rasoolinejad M, Forooghi M, Norouzi M, Poorebrahim M, Khamseh A, Karkhaneh M, Alavian SM, Ebrahimian A, Jazayeri SM. Molecular analysis of occult hepatitis B infection among Iranian HIV-positive patients. Future Virology 2016;11:497-508. [DOI: 10.2217/fvl-2016-0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
171 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
172 Ozaslan E. Which level of immunosuppression is harmful for occult hepatitis B virus infection? Liver Int 2009;29:1126-7; author reply 1127-8. [PMID: 19453947 DOI: 10.1111/j.1478-3231.2009.02050.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
173 Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, Auran T, Loundou A, Motte A, Ressiot E, Norguet E, Chabannon C, Bouabdallah R, Tamalet C, Gérolami R. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer: HBV reactivation following chemotherapy. Journal of Viral Hepatitis 2010;17:807-15. [DOI: 10.1111/j.1365-2893.2009.01239.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
174 Seo DH, Whang DH, Song EY, Han KS. Occult hepatitis B virus infection and blood transfusion. World J Hepatol 2015; 7(3): 600-606 [PMID: 25848484 DOI: 10.4254/wjh.v7.i3.600] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
175 Lau KC, Osiowy C, Coffin CS. Hepatitis B virus (HBV) genome detection and genotyping in virally suppressed patients using nested polymerase chain reaction-based Sanger sequencing. Diagnostic Microbiology and Infectious Disease 2019;93:318-24. [DOI: 10.1016/j.diagmicrobio.2018.10.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
176 Raouf HE, Yassin AS, Megahed SA, Ashour MS, Mansour TM. Seroprevalence of occult hepatitis B among Egyptian paediatric hepatitis C cancer patients. J Viral Hepat. 2015;22:103-111. [PMID: 24754376 DOI: 10.1111/jvh.12260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
177 Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol 2015; 21(42): 11931-11940 [PMID: 26576082 DOI: 10.3748/wjg.v21.i42.11931] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
178 Milazzo L, Corbellino M, Foschi A, Micheli V, Dodero A, Mazzocchi A, Montefusco V, Zehender G, Antinori S. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis. 2012;14:95-98. [PMID: 21749588 DOI: 10.1111/j.1399-3062.2011.00659.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
179 Rios-Ocampo WA, Cortes-Mancera F, Olarte JC, Soto A, Navas MC. Occult hepatitis B virus infection among blood donors in Colombia. Virol J 2014;11:206. [PMID: 25471066 DOI: 10.1186/s12985-014-0206-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
180 Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824-825. [PMID: 19664841 DOI: 10.1016/j.jhep.2009.06.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
181 Emara MH, Radwan MI. Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient. Virol J 2011;8:518. [PMID: 22078891 DOI: 10.1186/1743-422X-8-518] [Reference Citation Analysis]
182 Tian CH, Dai J, Zhang W, Liu Y, Yang Y. Expression of IL-17 and its gene promoter methylation status are associated with the progression of chronic hepatitis B virus infection. Medicine (Baltimore) 2019;98:e15924. [PMID: 31169710 DOI: 10.1097/MD.0000000000015924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
183 Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59:696-700. [PMID: 23751755 DOI: 10.1016/j.jhep.2013.05.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
184 Goyal A, Chauhan R. The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection. J Theor Biol 2018;455:269-80. [PMID: 29969598 DOI: 10.1016/j.jtbi.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
185 Gujar SA, Michalak TI. Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. J Virol 2009;83:3861-76. [PMID: 19193791 DOI: 10.1128/JVI.02521-08] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
186 Williams JB, Hüppner A, Mulrooney-Cousins PM, Michalak TI. Differential Expression of Woodchuck Toll-Like Receptors 1-10 in Distinct Forms of Infection and Stages of Hepatitis in Experimental Hepatitis B Virus Infection. Front Microbiol 2018;9:3007. [PMID: 30581424 DOI: 10.3389/fmicb.2018.03007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
187 Nishiya AS, Levi JE, de Almeida-Neto C, Witkin SS, Ferreira SC, Bassit L, Sabino EC, Di-Lorenzo-Oliveira C, Salles NA, Coutinho AS, Bellesa MA, Rocha V, Mendrone-Jr A. Occult and active hepatitis B virus detection in donated blood in São Paulo, Brazil. Transfusion 2021;61:1495-504. [PMID: 33687074 DOI: 10.1111/trf.16344] [Reference Citation Analysis]
188 Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol 2016;43:869-74. [PMID: 26879359 DOI: 10.3899/jrheum.151105] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
189 Liu CJ, Chen PJ, Chen DS. Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int. 2009;3:517-525. [PMID: 19669238 DOI: 10.1007/s12072-009-9147-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
190 Mallet V, van Bömmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P; ECIL-5. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016;16:606-17. [PMID: 27599653 DOI: 10.1016/S1473-3099(16)00118-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 30] [Article Influence: 17.4] [Reference Citation Analysis]
191 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
192 Cuenca-gómez JÁ, Cabezas-fernández MT, Soriano-pérez MJ, Salas-coronas J. Estudio de hepatitis B oculta en población inmigrante africana sin datos de hepatopatía. Medicina Clínica 2015;144:42-3. [DOI: 10.1016/j.medcli.2014.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Mandour M, Nemr N, Shehata A, Kishk R, Badran D, Hawass N. Occult HBV infection status among chronic hepatitis C and hemodialysis patients in Northeastern Egypt: regional and national overview. Rev Soc Bras Med Trop. 2015;48:258-264. [PMID: 26108002 DOI: 10.1590/0037-8682-0037-2015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
194 Dapena M, Figueras C, Noguera-Julian A, Fortuny C, de José MI, Mellado MJ, Gavilán C, Falcón-Neyra MD, Navarro ML, de Ory SJ. Implementation of occult hepatitis screening in the Spanish cohort of HIV-infected pediatric patients. Pediatr Infect Dis J. 2013;32:e377-e379. [PMID: 23446444 DOI: 10.1097/inf.0b013e31828e9b99] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
195 Chen X, Xiang K, Zhang H, Kong X, Huang C, Liu Y, Lou J, Gao Z, Yan H. Occult HBV infection in patients with autoimmune hepatitis: A virological and clinical study. Journal of Microbiology, Immunology and Infection 2020;53:946-54. [DOI: 10.1016/j.jmii.2019.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
196 Ricotti S, Garcia MI, Veaute C, Bailat A, Lucca E, Cook RF, Cook SJ, Soutullo A. Serologically silent, occult equine infectious anemia virus (EIAV) infections in horses. Veterinary Microbiology 2016;187:41-9. [DOI: 10.1016/j.vetmic.2016.03.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
197 Stramer SL, Krysztof DE, Brodsky JP, Fickett TA, Reynolds B, Dodd RY, Kleinman SH. Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion. 2013;53:2525-2537. [PMID: 23550838 DOI: 10.1111/trf.12178] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
198 Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, Kao JH, Chen DS, Liu CJ. The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study. Transfus Med. 2011;21:33-41. [PMID: 20726954 DOI: 10.1111/j.1365-3148.2010.01036.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
199 Nasir M, Wu GY. Prevention of HBV Recurrence after Liver Transplant: A Review. J Clin Transl Hepatol 2020;8:150-60. [PMID: 32832395 DOI: 10.14218/JCTH.2020.00003] [Reference Citation Analysis]
200 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
201 Afyon M, Artuk C. Is occult Hepatitis B virus infection with detectable anti-HBs infectious or not? Middle East J Dig Dis 2016;8:147-9. [PMID: 27252823 DOI: 10.15171/mejdd.2016.21] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
202 Makvandi M, Neisi N, Khalafkhany D, Makvandi K, Hajiani E, Shayesteh AA, Masjedi Zadeh A, Sina AH, Hamidifard M, Rasti M. Occult hepatitis B virus among the patients with abnormal alanine transaminase. Jundishapur J Microbiol. 2014;7:e11648. [PMID: 25485052 DOI: 10.5812/jjm.11648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
203 Scotto G, Fazio V, Nicola C. Occult Hepatitis B Infection in Recent Immigrants to Italy: Occult B Infection in Immigrants. J Community Health 2020;45:357-62. [PMID: 31555924 DOI: 10.1007/s10900-019-00746-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Tramuto F, Maida CM, Colomba GM, Di Carlo P, Vitale F. Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int. 2013;2013:859583. [PMID: 24063015 DOI: 10.1155/2013/859583] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
205 Olotu AA, Oyelese AO, Salawu L, Audu RA, Okwuraiwe AP, Aboderin AO. Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation. Virol J 2016;13:76. [PMID: 27150469 DOI: 10.1186/s12985-016-0533-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 De Paschale M, Manco MT, Belvisi L, Brando B, Latella S, Agrappi C, Mirri P, Gatti A, Clerici P. Prevalence of markers of hepatitis B virus infection or vaccination in HBsAg-negative subjects. Blood Transfus 2012;10:344-50. [PMID: 22682333 DOI: 10.2450/2012.0085-11] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
207 Liu Y, Zeng W, Xi J, Liu H, Liao H, Yu G, Chen X, Lu F. Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition. Journal of Hepatology 2019;70:557-9. [DOI: 10.1016/j.jhep.2018.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
208 European Association For The Study Of The Liver. [EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol. 2009;33:539-554. [PMID: 19481389 DOI: 10.1016/j.gcb.2009.03.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
209 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 161] [Article Influence: 57.3] [Reference Citation Analysis]
210 Roman S. Occult Hepatitis B and Other Unexplored Risk Factors for Hepatocellular Carcinoma in Latin America. Ann Hepatol 2018;17:541-3. [PMID: 29894289 DOI: 10.5604/01.3001.0012.0914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
211 Chemin I, Trépo C. Evolution of Hepatitis B and C serum markers: a still challenging issue. Liver Int 2011;31:905-7. [PMID: 21733079 DOI: 10.1111/j.1478-3231.2011.02479.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
212 Nagakawa O, Miyatomi Y, Shigeta Y, Inayama E, Murakami K, Sakai T, Kouno T, Masai M, Shirai K, Yoshida T. Occult Hepatitis B Virus Infection in Japanese Chronic Hemodialysis Patients: Occult HBV in Japanese HD Patients. Therapeutic Apheresis and Dialysis 2013;17:289-92. [DOI: 10.1111/1744-9987.12006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
213 Guarino M, Picardi M, Vitiello A, Pugliese N, Rea M, Cossiga V, Pane F, Caporaso N, Morisco F. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. Annals of Hepatology 2017;16:198-206. [DOI: 10.5604/16652681.1231579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
214 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 2014; 20(24): 7635-7643 [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
215 Pak K, Ordway S, Torres D. Occult HBV Infection: A Case Series at a Military Treatment Facility. Mil Med 2020;185:e795-8. [PMID: 31681958 DOI: 10.1093/milmed/usz379] [Reference Citation Analysis]
216 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
217 Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95:e4311. [PMID: 27472708 DOI: 10.1097/md.0000000000004311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
218 Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms 2020;8:E1819. [PMID: 33218205 DOI: 10.3390/microorganisms8111819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Yang MH, Li L, Hung YS, Hung CS, Allain JP, Lin KS, Tsai SJ. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion. 2010;50:65-74. [PMID: 19709394 DOI: 10.1111/j.1537-2995.2009.02357.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
220 Begini P, Cox MC, Angeletti S, Gigante E, Baccini F, Fonzo MD, Fave GD, Marignani M. Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. Scandinavian Journal of Infectious Diseases 2011;43:750-2. [DOI: 10.3109/00365548.2011.574149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
221 Eftekharian A, Moghaddasi H, Gachkar L, Amlashi SS. Detection of hepatitis B virus in the cerumen of patients with chronic hepatitis B infection. J Laryngol Otol. 2013;127:1065-1066. [PMID: 24131958 DOI: 10.1017/s0022215113002314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine 2015;33:4618-22. [DOI: 10.1016/j.vaccine.2015.06.076] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
223 European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2167] [Cited by in F6Publishing: 2062] [Article Influence: 240.8] [Reference Citation Analysis]
224 Pham TN, Michalak TI. Occult hepatitis C virus infection and its relevance in clinical practice. J Clin Exp Hepatol 2011;1:185-9. [PMID: 25755384 DOI: 10.1016/S0973-6883(11)60130-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
225 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
226 Keechilot CS, Shenoy V, Kumar A, Biswas L, Vijayrajratnam S, Dinesh K, Nair P. Detection of occult hepatitis B and window period infection among blood donors by individual donation nucleic acid testing in a tertiary care center in South India. Pathog Glob Health 2016;110:287-91. [PMID: 27788631 DOI: 10.1080/20477724.2016.1248171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
227 Xu Md F, Wang Md C, Shi Md X, Hou Md J, Guo Md X, Gao Md P. Resolution of HBV infection occurs sooner than recovery of renal disease in adult serum HBsAg-negative HBV-associated glomerulonephritis. J Med Virol 2018;90:1503-7. [PMID: 29718537 DOI: 10.1002/jmv.25211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
228 Stratta P, Bruschetta E, Minisini R, Barbè MC, Cornella C, Tognarelli G, Cena T, Magnani C, Fenoglio R, Toffolo K, Airoldi A, Pirisi M. Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation. Transplant Proc 2009;41:1132-7. [PMID: 19460498 DOI: 10.1016/j.transproceed.2009.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
229 Ma Q, Wang Y. Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol. 2012;84:198-206. [PMID: 22170538 DOI: 10.1002/jmv.23183] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
230 Wong DK, Cheng SCY, Mak LL, To EW, Lo RC, Cheung T, Seto W, Fung J, Man K, Lai C, Yuen M. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. Clinical Gastroenterology and Hepatology 2020;18:449-56. [DOI: 10.1016/j.cgh.2019.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
231 Buendia MA, Neuveut C. Hepatocellular carcinoma. Cold Spring Harb Perspect Med. 2015;5:a021444. [PMID: 25646384 DOI: 10.1101/cshperspect.a021444] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 9.8] [Reference Citation Analysis]
232 El Banna N, El Jisr T, Samaha H, El Chaar M. Low Prevalence of Occult Hepatitis B Infection Among Blood Donors in Beirut, Lebanon: Reconsider the Deferral Strategy of Anti-HBc Positive Blood Donors. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.14250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Svicher V, Cento V, Bernassola M, Neumann-fraune M, Hemert FV, Chen M, Salpini R, Liu C, Longo R, Visca M, Romano S, Micheli V, Bertoli A, Gori C, Ceccherini-silberstein F, Sarrecchia C, Andreoni M, Angelico M, Ursitti A, Spanò A, Zhang JM, Verheyen J, Cappiello G, Perno CF. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Research 2012;93:86-93. [DOI: 10.1016/j.antiviral.2011.10.022] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
234 Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris). 2010;58:254-257. [PMID: 20303674 DOI: 10.1016/j.patbio.2010.02.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
235 Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, Hamdy L, Tony EA. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon. 2012;12:253-258. [PMID: 22690232 DOI: 10.5812/hepatmon.5805] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
236 Minekawa T, Takehara S, Takahashi M, Okamoto H. Development of a highly sensitive bioluminescent enzyme immunoassay for hepatitis B virus surface antigen capable of detecting divergent mutants. Clin Vaccine Immunol 2013;20:1255-65. [PMID: 23761660 DOI: 10.1128/CVI.00186-13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
237 Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, Bhutia K, Gupta E, Mukhopadhyay CK, Dutta AK, Trivedi SS. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat 2013;20:801-10. [PMID: 24168259 DOI: 10.1111/jvh.12102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
238 Zhou S, Li T, Allain J, Zhou B, Zhang Y, Zhong M, Fu Y, Li C. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers. J Med Virol 2017;89:2130-7. [DOI: 10.1002/jmv.24861] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
239 Pollicino T, Raimondo G. Occult hepatitis B infection. J Hepatol 2014;61:688-9. [PMID: 24976111 DOI: 10.1016/j.jhep.2014.04.036] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
240 Minuk GY, Lerner B, Gibson SB, Johnston JB, Uhanova J, Andonov A, Wu J. Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemia. Can J Gastroenterol Hepatol 2014;28:131-4. [PMID: 24619633 DOI: 10.1155/2014/780350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
241 Chudy M, Hanschmann KM, Kress J, Nick S, Campos R, Wend U, Gerlich W, Nübling CM. First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. J Clin Virol 2012;55:303-9. [PMID: 22981623 DOI: 10.1016/j.jcv.2012.08.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
242 Miletić M, Bingulac-Popović J, Stojić Vidović M, Hećimović A, Berendika M, Babić I, Đogić V, Samardžija M, Barišić K, Jukić I, Mihaljević I. Anti-HBc prevalence among Croatian blood donors in a 14-year period (2004-2017): Assessment of trends, risks and need for implementing routine testing. Transfus Clin Biol 2019;26:257-62. [PMID: 31153786 DOI: 10.1016/j.tracli.2019.05.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
243 Eltom K, Albeely A, El Hussein ARM, Elkhidir IM, Enan K. Occult hepatitis B virus infection in Sudan: A systematic review and meta-analysis. JGH Open 2020;4:800-7. [PMID: 33102748 DOI: 10.1002/jgh3.12411] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Lee JJ, Kwon OS. [Occult hepatitis B virus infection and hepatocellular carcinoma]. Korean J Gastroenterol 2013;62:160-4. [PMID: 24077626 DOI: 10.4166/kjg.2013.62.3.160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
245 Mudawi H, Hussein W, Mukhtar M, Yousif M, Nemeri O, Glebe D, Kramvis A. Overt and occult hepatitis B virus infection in adult Sudanese HIV patients. International Journal of Infectious Diseases 2014;29:65-70. [DOI: 10.1016/j.ijid.2014.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
246 Huang X, Ma C, Zhang Q, Shi Q, Huang T, Liu C, Li J, Hollinger FB. Impact of "a" determinant mutations on detection of hepatitis B surface antigen (HBsAg) in HBV strains from Chinese patients with occult hepatitis B. J Med Virol 2017;89:1796-803. [PMID: 28513915 DOI: 10.1002/jmv.24859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
247 Zhang W, Huang J, Wang M, Song D, Liao Q, Rong X, Li T, Allain JP, Ren G, Fu Y, Li C. Characterization of monocytic and granulocytic subsets of myeloid-derived suppressor cells in blood donors with occult hepatitis B virus infection. J Med Virol 2019;91:330-5. [PMID: 29900634 DOI: 10.1002/jmv.25242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Muche M, Berg T, Rimpler S, Staedtler A, Böhm S, Nickel P, Baid-Agrawal S. Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. Liver Int 2019;39:263-70. [PMID: 30171739 DOI: 10.1111/liv.13951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
249 Bhargava A, Khan S, Panwar H, Pathak N, Punde RP, Varshney S, Mishra PK. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res. 2010;153:143-150. [PMID: 20667493 DOI: 10.1016/j.virusres.2010.07.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
250 de Gomes SA, Araujo NM, Flichman D, Campos R, Panduro A. Hepatitis B Viruses. In: Ludert JE, Pujol FH, Arbiza J, editors. Human Virology in Latin America. Cham: Springer International Publishing; 2017. pp. 309-31. [DOI: 10.1007/978-3-319-54567-7_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
251 Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204:39-55. [PMID: 25523195 DOI: 10.1007/s00430-014-0373-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
252 Gonçalves PL, Zago-Gomes Mda P, Gonçalves CS, Pereira FE. Hepatitis virus and hepatocellular carcinoma in Brazil: a report from the State of Espírito Santo. Rev Soc Bras Med Trop. 2014;47:559-563. [PMID: 25467255 DOI: 10.1590/0037-8682-0145-2014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
253 Amer F, Yousif MM, Mohtady H, Khattab RA, Karagoz E, Ayaz KFM, Hammad NM. Surveillance and impact of occult hepatitis B virus, SEN virus, and torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection. Int J Infect Dis 2020;92:13-8. [PMID: 31863879 DOI: 10.1016/j.ijid.2019.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
254 Zhang Z, Zhang L, Dai Y, Zhang Y, Li J, Li X. Occult hepatitis B virus infection: influence of S protein variants. Virol J 2016;13:10. [PMID: 26786229 DOI: 10.1186/s12985-016-0464-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
255 Li S, Xie M, Li W, Peng Q, Zhong B, Lu X, Ma Q. Prevalence of S gene mutations within the major hydrophilic region of hepatitis B virus in patients in Dongguan, southern China. Arch Virol 2017;162:2949-57. [DOI: 10.1007/s00705-017-3437-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
256 Roman S, Tanaka Y, Khan A, Kurbanov F, Kato H, Mizokami M, Panduro A. Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. J Med Virol. 2010;82:1527-1536. [PMID: 20648606 DOI: 10.1002/jmv.21846] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
257 Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, Sangiovanni A, Navarra G, Raimondo G, Pollicino T. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7. [DOI: 10.1111/liv.12807] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
258 Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol. 2016;50:691-703. [PMID: 27623512 DOI: 10.1097/mcg.0000000000000647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Jang JY, Park EJ. [Occult hepatitis B virus infection in chronic hepatitis C]. Korean J Gastroenterol 2013;62:154-9. [PMID: 24077625 DOI: 10.4166/kjg.2013.62.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
260 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
261 Gujar SA, Mulrooney-Cousins PM, Michalak TI. Repeated exposure to trace amounts of woodchuck hepadnavirus induces molecularly evident infection and virus-specific T cell response in the absence of serological infection markers and hepatitis. J Virol 2013;87:1035-48. [PMID: 23135718 DOI: 10.1128/JVI.01363-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
262 Hung WL, Wu JF, Ni YH, Chen HL, Chiang CL, Chang MH, Hsu HY. Occult hepatitis B virus and surface antigen mutant infection in healthy vaccinated cohorts and children with various forms of hepatitis and multiple transfusions. Liver Int 2019;39:1052-61. [PMID: 30790411 DOI: 10.1111/liv.14076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
263 David D, Raghavendran A, Goel A, Bharath Kumar C, Kodiatte TA, Burad D, Abraham P, Ramakrishna B, Joseph P, Ramachandran J, Eapen CE. Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India. Indian J Gastroenterol 2017;36:373-9. [PMID: 28975595 DOI: 10.1007/s12664-017-0785-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
264 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 32.0] [Reference Citation Analysis]
265 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
266 Yamaji K, Kai K, Komukai S, Koga H, Ide T, Kawaguchi A, Noshiro H, Aishima S. Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma. Hepatobiliary Surg Nutr 2018;7:443-53. [PMID: 30652089 DOI: 10.21037/hbsn.2018.10.01] [Reference Citation Analysis]
267 Song JE, Kim DY. Diagnosis of hepatitis B. Ann Transl Med. 2016;4:338. [PMID: 27761442 DOI: 10.21037/atm.2016.09.11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
268 Capezzuto C, Franchi E, Urbani S, Romanò L, Franchini M. Occult hepatitis B in blood donors: a description of two cases. Blood Transfus 2010;8:297-302. [PMID: 20967173 DOI: 10.2450/2010.0119-09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
269 Gao Z, Liu J, Fu P, Huang M, Cao R, Wen X, Zhang C, He T, Mao W, Liao D, Ke L, Yang Y, He M, Liu Y, Wang J, Dodd RY, Ness P, Shan H. Estimation of hepatitis B-positive rates in Chinese blood donors by combining predonation and postdonation screening results. Transfusion 2019;59:1749-54. [PMID: 30758046 DOI: 10.1111/trf.15158] [Reference Citation Analysis]
270 Ginzberg D, Wong RJ, Gish R. Global HBV burden: guesstimates and facts. Hepatol Int 2018;12:315-29. [DOI: 10.1007/s12072-018-9884-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
271 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
272 Gujar SA, Jenkins AK, Macparland SA, Michalak TI. Pre-acute hepadnaviral infection is associated with activation-induced apoptotic death of lymphocytes in the woodchuck (Marmota monax) model of hepatitis B. Developmental & Comparative Immunology 2010;34:999-1008. [DOI: 10.1016/j.dci.2010.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
273 Grossi G, Viganò M, Facchetti F, Labanca S, Loglio A, Dodero A, Montefusco V, Corradini P, Cafro A, Cairoli R, Colombo M, Lampertico P. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica 2017;102:e423-6. [PMID: 28659333 DOI: 10.3324/haematol.2017.168609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
274 Gusatti CS, Costi C, Halon ML, Grandi T, Medeiros AF, Silva CM, Gomes SA, Silva MS, Niel C, Rossetti ML. Hepatitis B Virus Genotype D Isolates Circulating in Chapecó, Southern Brazil, Originate from Italy. PLoS One 2015;10:e0135816. [PMID: 26275046 DOI: 10.1371/journal.pone.0135816] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
275 Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-592. [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022] [Cited by in Crossref: 353] [Cited by in F6Publishing: 341] [Article Influence: 29.4] [Reference Citation Analysis]
276 Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L; ICONA Foundation Study Group . HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infect Dis 2021;8:ofaa566. [PMID: 33447635 DOI: 10.1093/ofid/ofaa566] [Reference Citation Analysis]
277 Ozaras R, Mete B, Tabak F. Occult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017;15:605. [PMID: 27923721 DOI: 10.1016/j.cgh.2016.11.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
278 Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34. [PMID: 19681818 DOI: 10.1111/j.1365-2036.2009.04112.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.9] [Reference Citation Analysis]
279 Viet L, Husebekk A, Husum H, Skjerve E. Stochastic model for estimating the risk of transfusion-transmitted hepatitis B in Vietnam. Transfus Med 2013;23:423-31. [PMID: 23786316 DOI: 10.1111/tme.12053] [Reference Citation Analysis]
280 Min JA, Yoon Y, Lee HJ, Choi J, Kwon M, Kim K, Lee CU, Kim DJ, Yun H. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea. J Med Virol 2013;85:575-82. [PMID: 23364858 DOI: 10.1002/jmv.23523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
281 Trevillyan JM, Dennison A, Jenney A, Spelman D. Detection of hepatitis B virus DNA in serum is rare in the absence of hepatitis B surface antigen: impacts for detection and monitoring of chronic hepatitis B. Pathology 2014;46:69-71. [PMID: 24300718 DOI: 10.1097/PAT.0000000000000037] [Reference Citation Analysis]
282 Song SH, Hwang SG. [Occult hepatitis B virus infection: transmission and reactivation]. Korean J Gastroenterol 2013;62:148-53. [PMID: 24077624 DOI: 10.4166/kjg.2013.62.3.148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
283 Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS;  Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 56.5] [Reference Citation Analysis]
284 Shim CW, Park JW, Kim SH, Kim JS, Kim BH, Hong EK. Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. Therap Adv Gastroenterol. 2017;10:529-536. [PMID: 28804513 DOI: 10.1177/1756283x17710247] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
285 Huang FY, Wong DK, Seto WK, Zhang AY, Lee CK, Lin CK, Fung J, Lai CL, Yuen MF. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One. 2014;9:e99028. [PMID: 24901840 DOI: 10.1371/journal.pone.0099028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
286 Kato M, Atsumi T. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. Rheumatol Int 2016;36:635-41. [PMID: 26573663 DOI: 10.1007/s00296-015-3395-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
287 Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion-transmission risk. Transfus Clin Biol 2017;24:189-95. [PMID: 28673499 DOI: 10.1016/j.tracli.2017.06.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
288 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
289 Di Lello FA, Macías J, Cifuentes CC, Vargas J, Palomares JC, Pineda JA. Low prevalence of occult HBV infection among HIV-infected patients in Southern Spain. Enferm Infecc Microbiol Clin 2012;30:312-4. [PMID: 22071227 DOI: 10.1016/j.eimc.2011.09.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
290 Franz C, Perez Rde M, Zalis MG, Zalona AC, Rocha PT, Gonçalves RT, Nabuco LC, Villela-Nogueira CA. Prevalence of occult hepatitis B virus infection in kidney transplant recipients. Mem Inst Oswaldo Cruz. 2013;108:657-660. [PMID: 23903984 DOI: 10.1590/0074-0276108052013019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
291 Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. Eur J Gastroenterol Hepatol 2017;29:56-60. [PMID: 27669175 DOI: 10.1097/MEG.0000000000000749] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Carimo AA, Gudo ES, Maueia C, Mabunda N, Chambal L, Vubil A, Flora A, Antunes F, Bhatt N. First report of occult hepatitis B infection among ART naïve HIV seropositive individuals in Maputo, Mozambique. PLoS One 2018;13:e0190775. [PMID: 29320552 DOI: 10.1371/journal.pone.0190775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
293 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.8] [Reference Citation Analysis]
294 Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol 2015;21:24-31. [PMID: 25834799 DOI: 10.3350/cmh.2015.21.1.24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
295 Becker N, Schnitzler P, Boffetta P, Brennan P, Foretova L, Maynadié M, Nieters A, Staines A, Benavente Y, Cocco P, de Sanjose S. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study Epilymph. J Cancer Res Clin Oncol 2012;138:1993-2001. [DOI: 10.1007/s00432-012-1279-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
296 Cheng HR, Kao JH, Wu HL, Chen TC, Tseng TC, Liu CH, Su TH, Chen PJ, Chen DS, Liu CJ. Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. Liver Int. 2014;34:e71-e79. [PMID: 24119014 DOI: 10.1111/liv.12324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
297 Tang Y, Liu X, Lu X, He Q, Li G, Zou Y. Occult Hepatitis B Virus Infection in Maintenance Hemodialysis Patients: Prevalence and Mutations in "a" Determinant. Int J Med Sci 2020;17:2299-305. [PMID: 32922195 DOI: 10.7150/ijms.49540] [Reference Citation Analysis]
298 Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol 2016;26:285-303. [PMID: 27139263 DOI: 10.1002/rmv.1885] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
299 Gessoni G, Beggio S, Barin P, Favarato M, Galli C, Valverde S, Nata MB, Salvadego MM, Marchiori G. Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination. Blood Transfus. 2014;12 Suppl 1:s63-s68. [PMID: 23522882 DOI: 10.2450/2013.0227-12] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
300 White SL, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. Transplant Direct 2019;5:e416. [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
301 Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2010;16:809-17. [DOI: 10.1016/j.bbmt.2009.12.533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
302 Shaaban Hanafy A. Impact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia. Cytokine 2017;99:99-105. [PMID: 28802168 DOI: 10.1016/j.cyto.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
303 Lee SB, Kim KM, An J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2016;36:1351-1361. [PMID: 26913702 DOI: 10.1111/liv.13099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
304 Faria LC, Terrabuio DRB, Leblebicioglu H, Huprikar S. Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation 2018;102:S66-71. [PMID: 29381580 DOI: 10.1097/TP.0000000000002013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
305 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
306 Ryan K, Anderson M, Gyurova I, Ambroggio L, Moyo S, Sebunya T, Makhema J, Marlink R, Essex M, Musonda R, Gaseitsiwe S, Blackard JT. High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infect Dis 2017;4:ofx195. [PMID: 29062862 DOI: 10.1093/ofid/ofx195] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
307 Msomi N, Ndlovu K, Giandhari J, Wilkinson E, Parboosing R, Zungu S, Mlisana K. High rate of occult hepatitis B virus infection in hemodialysis units of KwaZulu-Natal, South Africa. J Med Virol 2019;91:1797-803. [PMID: 31180137 DOI: 10.1002/jmv.25510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
308 Han Z, Liu Y, Pan J, Bi Y, Liu J, Zhou YH. Occult hepatitis B virus infection with positive hepatitis B e antigen. Clin Chim Acta 2015;438:266-8. [PMID: 25218700 DOI: 10.1016/j.cca.2014.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
309 Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal of the American Academy of Dermatology 2017;77:88-97.e5. [DOI: 10.1016/j.jaad.2017.01.037] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
310 Lin CL, Chien RN, Lin SM, Ke PY, Lin CC, Yeh CT. An occult hepatitis B-derived hepatoma cell line carrying persistent nuclear viral DNA and permissive for exogenous hepatitis B virus infection. PLoS One 2013;8:e65456. [PMID: 23734258 DOI: 10.1371/journal.pone.0065456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
311 Varaklioti A, Kouramba A, Ioannidou P, Katsarou O. Occult hepatitis B virus infection in Greek patients with congenital bleeding disorders. Infect Genet Evol 2017;54:397-401. [PMID: 28705716 DOI: 10.1016/j.meegid.2017.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
312 Seri B, Minga A, Gabillard D, Dembele B, Konate S, Le Carrou J, Dohoun L, Abo Y, Karcher S, Coffie P, N'Dri-Yoman T, Attia A, Eholié SP, Danel C, Lacombe K, Anglaret X, Boyd A. Twenty-Year Evolution of Hepatitis B Virus and Human Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood Donors in Côte d'Ivoire. Open Forum Infect Dis 2018;5:ofy060. [PMID: 29644251 DOI: 10.1093/ofid/ofy060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
313 Lledó JL, Fernández C, Gutiérrez ML, Ocaña S. Management of occult hepatitis B virus infection: An update for the clinician. World J Gastroenterol 2011; 17(12): 1563-1568 [PMID: 21472122 DOI: 10.3748/wjg.v17.i12.1563] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
314 Nicolini LA, Zappulo E, Viscoli C, Mikulska M. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther 2018;16:227-41. [PMID: 29415584 DOI: 10.1080/14787210.2018.1438264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
315 Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med 2017;56:1967-71. [PMID: 28768965 DOI: 10.2169/internalmedicine.56.8233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
316 Minuk GY, Huynh C, Uhanova J, Osiowy C. Establishing diagnostic criteria for occult hepatitis B virus infections in community based populations. J Med Virol 2014;86:156-61. [PMID: 24132580 DOI: 10.1002/jmv.23813] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
317 Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol. 2015;63:1238-1253. [PMID: 26150256 DOI: 10.1016/j.jhep.2015.06.026] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 12.2] [Reference Citation Analysis]
318 Opaleye OO, Oluremi AS, Atiba AB, Adewumi MO, Mabayoje OV, Donbraye E, Ojurongbe O, Olowe OA. Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. J Trop Med. 2014;2014:796121. [PMID: 24868208 DOI: 10.1155/2014/796121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
319 Amponsah-Dacosta E, Selabe SG, Mphahlele MJ. Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients. J Med Virol 2018;90:291-303. [PMID: 28971485 DOI: 10.1002/jmv.24956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
320 Silva JL, de Souza VS, Vilella TA, Domingues AL, Coêlho MR. HBV and HCV serological markers in patients with the hepatosplenic form of mansonic schistosomiasis. Arq Gastroenterol 2011;48:124-30. [PMID: 21709954 DOI: 10.1590/s0004-28032011000200008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
321 Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238-244. [PMID: 23146778 DOI: 10.1016/j.dld.2012.09.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
322 Alvarez-Muñoz MT, Maldonado-Rodriguez A, Rojas-Montes O, Torres-Ibarra R, Gutierrez-Escolano F, Vazquez-Rosales G, Gomez A, Muñoz O, Torres J, Lira R. Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J Gastroenterol 2014; 20(37): 13530-13537 [PMID: 25309083 DOI: 10.3748/wjg.v20.i37.13530] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
323 Kwon OS, Jung YK, Bae KS, Kim JH, Kim SG, Kim YS, Lee JI, Lee JW, Kim YS. Anti-hepatitis B core positivity as a risk factor for hepatocellular carcinoma in alcoholic cirrhosis: a case-control study. Alcohol 2012;46:537-41. [PMID: 22572059 DOI: 10.1016/j.alcohol.2012.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
324 Saijo T, Joki N, Inishi Y, Muto M, Saijo M, Hase H. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial 2015;19:125-30. [PMID: 25363685 DOI: 10.1111/1744-9987.12241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
325 Guerrieri F, Belloni L, Pediconi N, Levrero M. Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 95-121. [DOI: 10.1007/978-3-319-22330-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
326 Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH, Hong SP, Park PW, Rim KS. Prevalence of occult hepatitis B virus infection in hemodialysis patients. Korean J Gastroenterol 2013;61:209-14. [PMID: 23624735 DOI: 10.4166/kjg.2013.61.4.209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
327 Allegra A, Penna G, Alonci A, Granata A, D'Angelo A, Musolino C. Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B. Med Oncol 2010;27:912-4. [PMID: 19771535 DOI: 10.1007/s12032-009-9305-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
328 Pinato DJ, Rossi D, Minh MT, Toniutto P, Boccato E, Minisini R, Gaidano G, Pirisi M. Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. Dig Liver Dis 2012;44:235-8. [PMID: 21996333 DOI: 10.1016/j.dld.2011.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
329 Hao Q, Wang Z, Wang Q, Chen B, Qian H, Liu X, Cao H, Xia W, Jiang J, Lu Z. Identification and characterization of lncRNA AP000253 in occult hepatitis B virus infection. Virol J 2021;18:125. [PMID: 34112188 DOI: 10.1186/s12985-021-01596-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
330 Hashemi SJ, Hajiani E, Masjedizadeh A, Makvandi M, Shayesteh AA, Alavinejad SP, Kadkhodaei A, Shahbazian H, Jasemi F, Karimi M. Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of Iran. Jundishapur J Microbiol. 2015;8:e16873. [PMID: 25861432 DOI: 10.5812/jjm.16873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
331 Eilard A, Andersson M, Ringlander J, Wejstål R, Norkrans G, Lindh M. Vertically acquired occult hepatitis B virus infection may become overt after several years. J Infect 2019;78:226-31. [PMID: 30658081 DOI: 10.1016/j.jinf.2019.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
332 Sosa-jurado F, Meléndez-mena D, Rosas-murrieta NH, Guzmán-flores B, Mendoza-torres MA, Barcenas-villalobos R, Márquez-domínguez L, Cortés-hernández P, Reyes-leyva J, Vallejo-ruiz V, Santos-lópez G, Chemin I. Effectiveness of PCR primers for the detection of occult hepatitis B virus infection in Mexican patients. PLoS ONE 2018;13:e0205356. [DOI: 10.1371/journal.pone.0205356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
333 Loglio A, Viganò M, Grossi G, Labanca S, Goldaniga M, Pompa A, Farina L, Rumi M, Corradini P, Facchetti F, Lunghi G, Baldini L, Lampertico P. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. Dig Liver Dis 2019;51:419-24. [PMID: 30316785 DOI: 10.1016/j.dld.2018.08.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
334 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
335 Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxì A, Di Stefano R. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int. 2009;29:1171-1177. [PMID: 19602139 DOI: 10.1111/j.1478-3231.2009.02071.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
336 Bruni R, Prosperi M, Marcantonio C, Amadori A, Villano U, Tritarelli E, Lo Presti A, Ciccozzi M, Ciccaglione AR. A computational approach to identify point mutations associated with occult hepatitis B: significant mutations affect coding regions but not regulative elements of HBV. Virol J. 2011;8:394. [PMID: 21824402 DOI: 10.1186/1743-422X-8-394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
337 Avellon A, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S, Martin D, McPherson S, Munoz-Chimeno M, Ryder S, Slapak G, Ryan P, Valbuena M, Kennedy PT. Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. J Med Virol 2020. [PMID: 32270883 DOI: 10.1002/jmv.25862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
338 Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59:696-700. [PMID: 23751755 DOI: 10.1016/j.jhep.2013.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
339 Yuan Q, Ou SH, Chen CR, Ge SX, Pei B, Chen QR, Yan Q, Lin YC, Ni HY, Huang CH. Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J Clin Microbiol. 2010;48:357-362. [PMID: 19940057 DOI: 10.1128/jcm.01781-09] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
340 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
341 Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol 2016; 22(1): 126-144 [PMID: 26755865 DOI: 10.3748/wjg.v22.i1.126] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 49] [Article Influence: 12.0] [Reference Citation Analysis]
342 Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608-614. [PMID: 21063484 DOI: 10.1007/s12072-010-9203-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
343 Niederhauser C. Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med 2011;2:91-102. [PMID: 22287868 DOI: 10.2147/JBM.S12899] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
344 Tsai T. Hepatitis B virus reactivation after ustekinumab treatment: reply from authors. Br J Dermatol 2014;170:478-9. [DOI: 10.1111/bjd.12613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
345 Becker N, Byl A, Friedrich S, Jauch A, Schnitzler P, Egerer G, Ho AD, Goldschmidt H, Neben K. Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma. Eur J Haematol 2013;90:279-85. [DOI: 10.1111/ejh.12018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
346 Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett. 2009;286:80-88. [PMID: 19683385 DOI: 10.1016/j.canlet.2009.07.013] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
347 Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int 2018;38 Suppl 1:115-21. [PMID: 29427482 DOI: 10.1111/liv.13640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
348 Mondelli MU, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? Front Immunol 2012;3:351. [PMID: 23420385 DOI: 10.3389/fimmu.2012.00351] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
349 Candotti D, El Chaar M, Allain J. Transfusion transmission of hepatitis B virus: still learning more about it: Transfusion transmission of hepatitis B virus. ISBT Science Series 2011;6:234-40. [DOI: 10.1111/j.1751-2824.2011.01493.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
350 Gerlich WH. Do we need better hepatitis B vaccines? Indian J Med Res 2017;145:414-9. [PMID: 28862172 DOI: 10.4103/ijmr.IJMR_1852_16] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
351 Portilho MM, Nabuco LC, Villela-Nogueira CA, Brandão-Mello CE, Pilotto JH, Flores GL, Lewis-Ximenez LL, Lampe E, Villar LM. Detection of occult hepatitis B in serum and oral fluid samples. Mem Inst Oswaldo Cruz 2018;113:62-5. [PMID: 29211108 DOI: 10.1590/0074-02760170071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
352 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
353 Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing. Transfus Med Hemother 2017;44:263-72. [PMID: 28924431 DOI: 10.1159/000460301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
354 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
355 Sarowar A, Hirode G, Janssen HLA, Feld JJ. Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. Clin Liver Dis 2021;25:805-16. [PMID: 34593154 DOI: 10.1016/j.cld.2021.06.007] [Reference Citation Analysis]
356 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10:239. [PMID: 23870415 DOI: 10.1186/1743-422x-10-239] [Cited by in Crossref: 152] [Cited by in F6Publishing: 73] [Article Influence: 19.0] [Reference Citation Analysis]
357 Jung HM, Jun DW, Min JY, Doo EY, Nam KW, Kwon YI, Kwon OW. A Case of Acute Hepatitis B by Occult HBV Infection without HbsAg Seroconversion. Korean J Med 2012;83:619. [DOI: 10.3904/kjm.2012.83.5.619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
358 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242. [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001] [Cited by in Crossref: 1092] [Cited by in F6Publishing: 1015] [Article Influence: 84.0] [Reference Citation Analysis]
359 Seed CR, Allain JP, Lozano M, Laperche S, Gallian P, Gross S, Kwon SY, Oh EY, Kim JN, Chua SS, Lam S, Ang AL, Tsoi WC, Hewitt PE, Davison K, Tettmar K, O'Flaherty N, Boland F, Williams P, Pomeroy L, Wendel S, Fachini R, Scuracchio PSP, Carminato P, Fearon M, O'Brien SF, Delages G, Kiely P, Hoad VC, Matsubayashi K, Satake M, Taira R, Stramer SL, Sauleda S, Bes M, Piron M, Ekiaby ME, Vermeulen M, Stezinar SL, Nograšek P, Jarvis LM, Petrik J, Charlewood R, Flanagan P, Grabarczyk P, Kopacz A, Łętowska M, Schmidt M, Seifried E. International forum on Occult hepatitis B infection and transfusion safety. Vox Sang 2019;114:397-406. [PMID: 30818422 DOI: 10.1111/vox.12744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
360 Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol 2011; 3(12): 292-299 [PMID: 22216369 DOI: 10.4254/wjh.v3.i12.292] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
361 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289 [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
362 Wu D, Wang X, Feng F, Wang D, Hu Y, Yu Y, Huang J, Wang M, Dong J, Wu Y, Zhu H, Zhu F. Characteristic of HBV nucleic acid amplification testing yields from blood donors in China. BMC Infect Dis 2021;21:714. [PMID: 34330225 DOI: 10.1186/s12879-021-06468-y] [Reference Citation Analysis]
363 Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion. 2009;49:1621-1629. [PMID: 19413737 DOI: 10.1111/j.1537-2995.2009.02188.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
364 Ie SI, Turyadi, Sidarta E, Sadhewa A, Purnomo GA, Soedarmono YS, Pattiiha MZ, Thedja MD, Harahap AR, Muljono DH. High Prevalence of Hepatitis B Virus Infection in Young Adults in Ternate, Eastern Indonesia. Am J Trop Med Hyg 2015;93:1349-55. [PMID: 26392157 DOI: 10.4269/ajtmh.15-0331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
365 Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, Terrault NA. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18:415-423. [PMID: 20626626 DOI: 10.1111/j.1365-2893.2010.01321.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
366 Datta S, Khillan K, Ranjan V, Wattal C. Nucleic acid amplification test: Bridging the gap in blood safety & re-evaluation of blood screening for cryptic transfusion-transmitted infection among Indian donors. Indian J Med Res 2019;149:389-95. [PMID: 31249205 DOI: 10.4103/ijmr.IJMR_1340_17] [Reference Citation Analysis]
367 Elbahrawy A, Alaboudy A, El Moghazy W, Elwassief A, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol 2015; 7(12): 1671-1678 [PMID: 26140086 DOI: 10.4254/wjh.v7.i12.1671] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
368 Ferrari TC, Xavier MA, Vidigal PV, Amaral NS, Diniz PA, Resende AP, Miranda DM, Faria AC, Lima AS, Faria LC. Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz J Med Biol Res. 2014;47:990-994. [PMID: 25296362 DOI: 10.1590/1414-431x20143782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
369 Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, Brojer E, Erikstrup C, Saniewski M, Wernish L, Bianco L, Ullum H, Candotti D, Lelie N, Gerlich WH, Chudy M. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013;53:1405-15. [PMID: 23362802 DOI: 10.1111/trf.12096] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 11.0] [Reference Citation Analysis]
370 Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:479-484. [PMID: 20848520 DOI: 10.1002/ibd.21336] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
371 Oluyinka OO, Tong HV, Bui Tien S, Fagbami AH, Adekanle O, Ojurongbe O, Bock CT, Kremsner PG, Velavan TP. Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS One. 2016;10:e0131912. [PMID: 26148052 DOI: 10.1371/journal.pone.0131912] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
372 Wong DK, Fung J, Lee CK, Seto WK, Leung J, Huang FY, Lin CK, Lai CL, Yuen MF. Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. Clin Microbiol Infect 2016;22:290.e1-3. [PMID: 26585773 DOI: 10.1016/j.cmi.2015.10.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
373 Gededzha MP, Sondlane TH, Malinga LA, Burnett RJ, Lebelo RL, Blackard JT, Mphahlele MJ, Selabe SG. Molecular characterization of hepatitis B virus X gene in HIV-positive South Africans. Virus Genes 2018;54:190-8. [PMID: 29411271 DOI: 10.1007/s11262-018-1536-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Srivastava A, Mathias A, Yachha SK, Aggarwal R. Occult hepatitis B infection in children with chronic liver disease. Eur J Gastroenterol Hepatol. 2015;27:375-377. [PMID: 25874508 DOI: 10.1097/meg.0000000000000294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
375 Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S. Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver Int. 2014;34:e144-e150. [PMID: 24502524 DOI: 10.1111/liv.12482] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
376 Raimondo G, Pollicino T. Occult HBV Infection. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 277-301. [DOI: 10.1007/978-3-319-22330-8_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
377 Wang Y, Chen T, Lu LL, Wang M, Wang D, Yao H, Fan C, Qi J, Zhang Y, Qu C. Adolescent booster with hepatitis B virus vaccines decreases HBV infection in high-risk adults. Vaccine 2017;35:1064-70. [PMID: 28069363 DOI: 10.1016/j.vaccine.2016.12.062] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
378 Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. Hepatitis B serological markers and plasma DNA concentrations. AIDS 2017;31:1109-17. [PMID: 28328795 DOI: 10.1097/QAD.0000000000001454] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
379 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
380 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
381 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
382 Feeney SA, Mccaughey C, Watt AP, Agnaf MRE, Mcdougall N, Wend UC, Gerlich WH, Coyle PV. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 2013;85:597-601. [DOI: 10.1002/jmv.23513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
383 Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, Liu X, Deng Q, Li L. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol Oncol 2021;39:75-86. [PMID: 32949412 DOI: 10.1002/hon.2807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
384 Kim JW. Occult hepatitis B virus infection: clearance or disguise? Clin Mol Hepatol 2014;20:249-50. [PMID: 25320727 DOI: 10.3350/cmh.2014.20.3.249] [Reference Citation Analysis]
385 Indolfi G, Nesi A, Resti M. Treatment of chronic hepatitis B and C in children. Future Virology 2012;7:955-72. [DOI: 10.2217/fvl.12.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
386 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 330] [Cited by in F6Publishing: 334] [Article Influence: 82.5] [Reference Citation Analysis]
387 Biswas S, Candotti D, Allain JP. Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J Virol. 2013;87:7882-7892. [PMID: 23658444 DOI: 10.1128/jvi.00710-13] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
388 Solves P, Mirabet V, Alvarez M. Hepatitis B transmission by cell and tissue allografts: How safe is safe enough? World J Gastroenterol 2014; 20(23): 7434-7441 [PMID: 24966613 DOI: 10.3748/wjg.v20.i23.7434] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
389 El-Maksoud MA, Habeeb MR, Ghazy HF, Nomir MM, Elalfy H, Abed S, Zaki MES. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2019;31:716-722. [PMID: 30870221 DOI: 10.1097/meg.0000000000001388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
390 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
391 Kew MC. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol 2010; 2(2): 65-73 [PMID: 21160975 DOI: 10.4254/wjh.v2.i2.65] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
392 Li Y, Wang H, Li D, Hu J, Zhou D, Li Q, Jiang X, Zhou H, Hu H. Occult hepatitis B virus infection in Chinese cryptogenic intrahepatic cholangiocarcinoma patient population. J Clin Gastroenterol. 2014;48:878-882. [PMID: 24356457 DOI: 10.1097/mcg.0000000000000058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
393 Helaly GF, El Ghazzawi EF, Shawky SM, Farag FM. Occult hepatitis B virus infection among chronic hemodialysis patients in Alexandria, Egypt. J Infect Public Health 2015;8:562-9. [PMID: 26026236 DOI: 10.1016/j.jiph.2015.04.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
394 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
395 Lu Y, Liu YL, Nie JJ, Liang XF, Yan L, Wang FZ, Zhai XJ, Liu JX, Zhu FC, Chang ZJ, Li J. Occult HBV Infection in Immunized Neonates Born to HBsAg-Positive Mothers: A Prospective and Follow-Up Study. PLoS One 2016;11:e0166317. [PMID: 27835694 DOI: 10.1371/journal.pone.0166317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
396 Escobedo-meléndez G, Fierro NA, Roman S, Maldonado-gonzález M, Zepeda-carrillo E, Panduro A. Prevalence of hepatitis A, B and C serological markers in children from western Mexico. Annals of Hepatology 2012;11:194-201. [DOI: 10.1016/s1665-2681(19)31024-5] [Cited by in Crossref: 16] [Article Influence: 1.8] [Reference Citation Analysis]
397 Fontenele AM, Filho NS, Ferreira AS. Occult hepatitis B in patients on hemodialysis: a review. Annals of Hepatology 2013;12:359-63. [DOI: 10.1016/s1665-2681(19)31335-3] [Cited by in Crossref: 15] [Article Influence: 1.9] [Reference Citation Analysis]
398 Zhuge S, Ge C, Yang Y, Cui Y, Yue X, Zhang Z, Xu H, Huang A, Zhao Y. The prevalence of occult HBV infection in immunized children with HBsAg-positive parents: a hospital-based analysis. Hepatol Int 2020;14:503-12. [PMID: 32472310 DOI: 10.1007/s12072-020-10055-9] [Reference Citation Analysis]
399 Costantini A, Marinelli K, Biagioni G, Monachetti A, Ferreri ML, Butini L, Montroni M, Manzin A, Bagnarelli P. Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infect Dis. 2011;11:310. [PMID: 22054111 DOI: 10.1186/1471-2334-11-310] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
400 Brancaccio G, Nardi A, Madonia S, Fasano M, Verucchi G, Massari M, Maimone S, Contini C, Levantesi F, Alfieri A, Gavrila C, Andreone P, Milella M, Gaeta GB. The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort. Dig Liver Dis 2019;51:438-42. [PMID: 30314950 DOI: 10.1016/j.dld.2018.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
401 Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011;18:461-6. [PMID: 21912252 DOI: 10.1097/MOH.0b013e32834bac10] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
402 Pollicino T, Musolino C, Saitta C, Tripodi G, Lanza M, Raffa G, Tocco FCD, Raggi C, Bragazzi MC, Barbera A, Navarra G, Invernizzi P, Alvaro D, Raimondo G. Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget. 2019;10:3931-3938. [PMID: 31231470 DOI: 10.18632/oncotarget.27002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
403 Tang X, Allain JP, Wang H, Rong X, Chen J, Huang K, Xu R, Wang M, Huang J, Liao Q, Shan Z, Luo S, Li T, Li C, Fu Y. Incidence of hepatitis B virus infection in young Chinese blood donors born after mandatory implementation of neonatal hepatitis B vaccination nationwide. J Viral Hepat 2018;25:1008-16. [PMID: 29624818 DOI: 10.1111/jvh.12901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
404 Ozaslan E, Purnak T. Controversies about occult hepatitis B virus infection. World J Gastroenterol 2009; 15(39): 4986-4987 [PMID: 19842236 DOI: 10.3748/wjg.15.4986] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
405 Wang H, Fang M, Gu X, Ji Q, Li D, Cheng SQ, Shen F, Gao CF. The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PLoS One. 2014;9:e107162. [PMID: 25229710 DOI: 10.1371/journal.pone.0107162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
406 Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Des Devel Ther 2018;12:3767-74. [PMID: 30464407 DOI: 10.2147/DDDT.S181561] [Reference Citation Analysis]
407 Laurenti L, Autore F, Innocenti I, Vannata B, Piccirillo N, Sorà F, Speziale D, Pompili M, Efremov D, Sica S. Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. Leuk Lymphoma 2015;56:2841-6. [PMID: 25682966 DOI: 10.3109/10428194.2015.1017822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
408 Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, Uchida S, Tadokoro K. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion. 2013;53:1393-1404. [PMID: 23033944 DOI: 10.1111/j.1537-2995.2012.03909.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 6.8] [Reference Citation Analysis]
409 Rosa AS, Araujo OC, Savassi-Ribas F, Fernandes CA, Coelho HS, Niel C, Villela-Nogueira CA, Araujo NM. Prevalence of occult hepatitis B virus infection and Torque teno virus infection and their association with hepatocellular carcinoma in chronic hepatitis C patients. Virus Res. 2017;242:166-172. [PMID: 28966070 DOI: 10.1016/j.virusres.2017.09.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
410 Wu J, Han M, Li J, Yang X, Yang D. Immunopathogenesis of HBV Infection. In: Tang H, editor. Hepatitis B Virus Infection. Singapore: Springer; 2020. pp. 71-107. [DOI: 10.1007/978-981-13-9151-4_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
411 Wang H, Xiang Y, Li X, Liu S, Liu L. High lymphocyte‑to‑monocyte ratio is associated with low α‑fetoprotein expression in patients with hepatitis B virus‑associated hepatocellular carcinoma. Mol Med Rep 2020;22:2673-84. [PMID: 32945410 DOI: 10.3892/mmr.2020.11387] [Reference Citation Analysis]
412 Zhang Z, Zhang Y, Xu N, Huang C, Li X, Li J. High risk of occult hepatitis B virus infection in leukemia patients from China. Arch Virol 2017;162:349-57. [PMID: 27743257 DOI: 10.1007/s00705-016-3111-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
413 Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12:193-207. [DOI: 10.1517/14712598.2012.646986] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
414 Romanò L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR; SIMTI study group for HBV infection among first-time blood donors. Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus. 2013;11:281-288. [PMID: 23399361 DOI: 10.2450/2012.0160-12] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
415 Sarmati L, Malagnino V. HBV Infection in HIV-Driven Immune Suppression. Viruses 2019;11:E1077. [PMID: 31752284 DOI: 10.3390/v11111077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
416 Semenov AV, Ostankova YV, Serikova EN, Zueva EB, Totolian AA. Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection. Klin Lab Diagn 2020;65:574-9. [PMID: 33245644 DOI: 10.18821/0869-2084-2020-65-9-574-579] [Reference Citation Analysis]
417 Abd El Kader Mahmoud O, Abd El Rahim Ghazal A, El Sayed Metwally D, Elnour AM, Yousif GE. Detection of occult hepatitis B virus infection among blood donors in Sudan. J Egypt Public Health Assoc 2013;88:14-8. [PMID: 23528527 DOI: 10.1097/01.EPX.0000427065.73965.c8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
418 Liu Y, Li P, Li C, Zhou J, Wu C, Zhou YH. Detection of hepatitis B virus DNA among accepted blood donors in Nanjing, China. Virol J. 2010;7:193. [PMID: 20718994 DOI: 10.1186/1743-422x-7-193] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
419 Loglio A, Viganò M, Lampertico P. Novel Therapies That May Cure Chronic Hepatitis B Virus. Clin Liver Dis 2021;25:875-99. [PMID: 34593159 DOI: 10.1016/j.cld.2021.07.001] [Reference Citation Analysis]
420 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
421 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
422 Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40-46. [PMID: 25613809 DOI: 10.1002/hep.27716] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
423 Said ZNA. An overview of occult hepatitis B virus infection. World J Gastroenterol 2011; 17(15): 1927-1938 [PMID: 21528070 DOI: 10.3748/wjg.v17.i15.1927] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 84] [Article Influence: 9.8] [Reference Citation Analysis]
424 Chemin I. Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development. Future Oncology 2010;6:21-3. [DOI: 10.2217/fon.09.158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
425 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
426 Shrestha S, Tiwari PS, Pradhan B. Occult Hepatitis B Infection in End-Stage Renal Disease Patients Starting Maintenance Hemodialysis at a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 2021;59:336-41. [PMID: 34508536 DOI: 10.31729/jnma.5723] [Reference Citation Analysis]
427 Wu ZF, Xu Z, Li WS, Zhang HB, Yang N, Yao XQ, Liu FK, Yang GS. Impact of occult hepatitis B virus infection on outcome after resection for non-B non-C hepatocellular carcinoma. J Surg Res 2015;193:153-60. [PMID: 25128925 DOI: 10.1016/j.jss.2014.07.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
428 Wiegand J, Meya S, Schlaphoff V, Manns MP, Mössner J, Wedemeyer H, Tillmann HL. HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat 2010;17:631-9. [PMID: 19889141 DOI: 10.1111/j.1365-2893.2009.01220.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
429 Tsoi WC, Lelie N, Lin CK. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay. Transfusion 2013;53:2477-88. [PMID: 23521050 DOI: 10.1111/trf.12165] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
430 Locarnini S, Raimondo G. How infectious is the hepatitis B virus? Readings from the occult. Gut 2019;68:182-3. [PMID: 30068661 DOI: 10.1136/gutjnl-2018-316900] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
431 Besharat S, Katoonizadeh A, Moradi A. Potential mutations associated with occult hepatitis B virus status. Hepat Mon. 2014;14:e15275. [PMID: 24829588 DOI: 10.5812/hepatmon.15275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
432 Launay O, Masurel J, Servant-Delmas A, Basse-Guérineau AL, Méritet JF, Laperche S, Sogni P, Rosenberg AR. High levels of serum hepatitis B virus DNA in patients with ‘anti-HBc alone’: role of HBsAg mutants. J Viral Hepat. 2011;18:721-729. [PMID: 21914087 DOI: 10.1111/j.1365-2893.2011.01482.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
433 Cho J, Lee SS, Choi YS, Jeon Y, Chung JW, Baeg JY, Si WK, Jang ES, Kim JW, Jeong SH. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection. World J Gastroenterol 2016; 22(42): 9427-9436 [PMID: 27895431 DOI: 10.3748/wjg.v22.i42.9427] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
434 Wang H, Wang M, Huang J, Xu R, Liao Q, Shan Z, Zheng Y, Rong X, Tang X, Li T, Wang W, Li C, Fu Y. Novel hepatitis B virus surface antigen mutations associated with occult genotype B hepatitis B virus infection affect HBsAg detection. J Viral Hepat 2020;27:915-21. [PMID: 32336003 DOI: 10.1111/jvh.13309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
435 Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 2014; 20(40): 14559-14567 [PMID: 25356020 DOI: 10.3748/wjg.v20.i40.14559] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
436 Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
437 Ie SI, Thedja MD, Roni M, Muljono DH. Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors. Virol J 2010;7:326. [PMID: 21087462 DOI: 10.1186/1743-422X-7-326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
438 Ozoya OO, Chavez J, Sokol L, Dalia S. Optimizing antiviral agents for hepatitis B management in malignant lymphomas. Ann Transl Med 2017;5:39. [PMID: 28251118 DOI: 10.21037/atm.2016.12.25] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
439 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
440 Shchemelev AN, Ostankova YV, Zueva EB, Boumbaly S, Balde TA, Semenov AV. Characterization of Hepatitis B Virus and Human Immunodeficiency Virus among HIV/HBV Co-Infected Patients from the Republic of Guinea. Problemy Osobo Opasnykh Infektsii 2019. [DOI: 10.21055/0370-1069-2019-3-118-124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
441 Taffon S, Genovese D, Blasi M, Pierotti P, Degli Esposti A, Catone S, Chionne P, Pulimanti B, Candido A, Dettori S, Tosti ME, Argentini C, Mazzotta F, Rapicetta M. HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study. Infection 2014;42:675-87. [PMID: 24700252 DOI: 10.1007/s15010-014-0616-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
442 Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis. 2011;32:1122-1132. [PMID: 21665892 DOI: 10.1093/carcin/bgr108] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
443 Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol. 2015;204:5-10. [PMID: 25540037 DOI: 10.1007/s00430-014-0369-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
444 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
445 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22(39): 8720-8734 [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 60] [Article Influence: 14.4] [Reference Citation Analysis]
446 Power JP, El Chaar M, Temple J, Thomas M, Spillane D, Candotti D, Allain JP. HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus. J Hepatol. 2010;53:780-787. [PMID: 20638744 DOI: 10.1016/j.jhep.2010.04.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
447 Wang J, Zhang P, Zeng J, Du P, Zheng X, Ye X, Zhu W, Fu Y, Candotti D, Allain JP, Li C, Li T. Occurrence of occult hepatitis B virus infection associated with envelope protein mutations according to anti-HBs carriage in blood donors. Int J Infect Dis 2020;92:38-45. [PMID: 31877352 DOI: 10.1016/j.ijid.2019.12.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
448 Orlando R, Foggia M, Maraolo AE, Mascolo S, Palmiero G, Tambaro O, Tosone G. Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis. 2015;34:1059-1070. [PMID: 25678010 DOI: 10.1007/s10096-015-2341-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
449 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 16.8] [Reference Citation Analysis]
450 Jose-Abrego A, Panduro A, Fierro NA, Roman S. High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status. J Med Virol 2017;89:2149-57. [PMID: 28792071 DOI: 10.1002/jmv.24913] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
451 Thng C, Babiker ZO, Brown B, Babu C. The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV. Int J STD AIDS 2012;23:149-50. [PMID: 22422696 DOI: 10.1258/ijsa.2011.011205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
452 Yao QQ, Dong XL, Wang XC, Ge SX, Hu AQ, Liu HY, Wang YA, Yuan Q, Zheng YJ. Hepatitis B virus surface antigen (HBsAg)-positive and HBsAg-negative hepatitis B virus infection among mother-teenager pairs 13 years after neonatal hepatitis B virus vaccination. Clin Vaccine Immunol. 2013;20:269-275. [PMID: 23254298 DOI: 10.1128/cvi.00539-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
453 Gupta A, Punatar S, Gawande J, Bagal B, Mathew L, Bhat V, Kannan S, Khattry N. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. Hematol Oncol 2016;34:140-6. [PMID: 25690950 DOI: 10.1002/hon.2195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
454 Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int 2019;39:1986-98. [PMID: 31172639 DOI: 10.1111/liv.14168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
455 Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84 Suppl 1:17-22. [PMID: 22156481 DOI: 10.1159/000333210] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
456 Wang Q, Xu ZQ, Fu JJ, Pan XC. Hepatitis B virus reactivation recurred after the cessation of entecavir in an allogenetic hematopoietic stem cell transplantation patient. Clin Res Hepatol Gastroenterol 2017;41:e48-50. [PMID: 28647338 DOI: 10.1016/j.clinre.2017.05.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Fierro NA, Roman S, Realpe M, Hernandez-Nazara Z, Zepeda-Carrillo EA, Panduro A. Multiple cytokine expression profiles reveal immune-based differences in occult hepatitis B genotype H-infected Mexican Nahua patients. Mem Inst Oswaldo Cruz. 2011;106:1007-1013. [PMID: 22241125 DOI: 10.1590/s0074-02762011000800018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
458 Chen Y, Li L, Zhou Z, Wang N, Zhang CY, Zen K. A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection. Med Microbiol Immunol. 2012;201:389-395. [PMID: 22392036 DOI: 10.1007/s00430-011-0223-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
459 Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Selabe SG, Gededzha MP, Mayaphi SH, Powell EA, Blackard JT, Mphahlele MJ. Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants. J Clin Virol 2015;63:12-7. [PMID: 25600597 DOI: 10.1016/j.jcv.2014.11.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
460 Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G, Gill MJ. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol. 2014;60:347-353. [PMID: 24881491 DOI: 10.1016/j.jcv.2014.04.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
461 María García-montalvo B, Patricia Ventura-zapata L. Molecular and serological characterization of occult hepatitis B infection in blood donors from Mexico. Annals of Hepatology 2011;10:133-41. [DOI: 10.1016/s1665-2681(19)31561-3] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
462 Niederhauser C, Candotti D, Weingand T, Maier A, Tinguely C, Stolz M, Allain JP. Reverse vertical transmission of hepatitis B virus (HBV) infection from a transfusion-infected newborn to her mother. J Hepatol 2012;56:734-7. [PMID: 22027580 DOI: 10.1016/j.jhep.2011.07.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
463 Manzini P, Abate ML, Valpreda C, Milanesi P, Curti F, Rizzetto M, Smedile A. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 2009;49:757-64. [DOI: 10.1111/j.1537-2995.2008.02041.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
464 Larrubia JR. Occult hepatitis B virus infection: A complex entity with relevant clinical implications. World J Gastroenterol 2011; 17(12): 1529-1530 [PMID: 21472115 DOI: 10.3748/wjg.v17.i12.1529] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
465 Mak D, Kramvis A. Molecular characterization of hepatitis B virus isolated from Black South African cancer patients, with and without hepatocellular carcinoma. Arch Virol 2020;165:1815-25. [PMID: 32504396 DOI: 10.1007/s00705-020-04686-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 31.0] [Reference Citation Analysis]
467 Seed CR, Jones NT, Pickworth AM, Graham WR. Two cases of asymptomatic HBV "vaccine breakthrough" infection detected in blood donors screened for HBV DNA. Med J Aust 2012;196:651-2. [PMID: 22676882 DOI: 10.5694/mja11.11589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
468 Ostankova YO, Semenov AV, Zueva EB, Totolian AA. THE PREVALENCE OF OCCULT HEPATITIS B AMONG HBSAG-NEGATIVE PERSONS WITH HIV IN VELIKY NOVGOROD. VIČ-infekc immunosupr 2019;11:64-70. [DOI: 10.22328/2077-9828-2019-11-1-64-70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
469 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
470 Prieto M. Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal: Editorial. Liver Transpl 2009;15:1164-8. [DOI: 10.1002/lt.21814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
471 Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875-880. [PMID: 21684821 DOI: 10.1016/j.dld.2011.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
472 Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tayou Tagny C, Bloch EM. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. Transfus Med Rev 2015;29:35-44. [PMID: 25447555 DOI: 10.1016/j.tmrv.2014.09.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
473 Schüttler CG, Wend UC, Faupel FM, Lelie PN, Gerlich WH. Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). J Clin Virol 2010;47:238-42. [PMID: 20117963 DOI: 10.1016/j.jcv.2009.12.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
474 Mulrooney-Cousins PM, Michalak TI. Asymptomatic Hepadnaviral Persistence and Its Consequences in the Woodchuck Model of Occult Hepatitis B Virus Infection. J Clin Transl Hepatol. 2015;3:211-219. [PMID: 26623268 DOI: 10.14218/jcth.2015.00020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
475 Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis. 2013;45:683-686. [PMID: 23490344 DOI: 10.1016/j.dld.2013.01.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
476 Lee SS, Jeong S, Jang ES, Kim YS, Lee YJ, Jung EU, Kim IH, Bae SH, Lee HC, Kee M, Kang C. Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea: Outcomes of HCV-related cirrhosis. J Gastroenterol Hepatol 2015;30:1281-7. [DOI: 10.1111/jgh.12950] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
477 Makondo E, Bell TG, Kramvis A. Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa. PLoS One. 2012;7:e46345. [PMID: 23029487 DOI: 10.1371/journal.pone.0046345] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
478 Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51:798-809. [PMID: 19615780 DOI: 10.1016/j.jhep.2009.05.020] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 9.6] [Reference Citation Analysis]
479 Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011;9:891-899. [PMID: 21973301 DOI: 10.1586/eri.11.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
480 Ayana DA, Mulu A, Mihret A, Seyoum B, Aseffa A, Howe R. Occult Hepatitis B virus infection among HIV negative and positive isolated anti-HBc individuals in eastern Ethiopia. Sci Rep 2020;10:22182. [PMID: 33335238 DOI: 10.1038/s41598-020-79392-x] [Reference Citation Analysis]
481 Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt--that is the question. PLoS One. 2012;7:e45750. [PMID: 23049685 DOI: 10.1371/journal.pone.0045750] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
482 Musa MD, Ateya HK. Prevalence of overt and occult hepatitis B virus infections among 135 haemodialysis patients attending a haemodialysis centre at Al-Nasiriyah city, Iraq. Iran J Microbiol 2020;12:475-82. [PMID: 33604004 DOI: 10.18502/ijm.v12i5.4610] [Reference Citation Analysis]
483 Chen J, Liu B, Tang X, Zheng X, Lu J, Zhang L, Wang W, Candotti D, Fu Y, Allain JP, Li C, Li L, Li T. Role of core protein mutations in the development of occult HBV infection. J Hepatol 2021;74:1303-14. [PMID: 33453326 DOI: 10.1016/j.jhep.2020.12.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
484 Liu C, Chang L, Ji H, Guo F, Zhang K, Lin G, Zhang R, Li J, Wang L. Prevalence of HBV DNA among 20 million seronegative blood donations in China from 2010 to 2015. Sci Rep. 2016;6:36464. [PMID: 27833112 DOI: 10.1038/srep36464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
485 Kim YS. [Definition, diagnosis, and prevalence of occult hepatitis B virus infection]. Korean J Gastroenterol 2013;62:143-7. [PMID: 24077623 DOI: 10.4166/kjg.2013.62.3.143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
486 Yousif M, Mudawi H, Hussein W, Mukhtar M, Nemeri O, Glebe D, Kramvis A. Genotyping and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan. Int J Infect Dis. 2014;29:125-132. [PMID: 25449246 DOI: 10.1016/j.ijid.2014.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
487 Komatsu H, Inui A. Hepatitis B virus infection in children. Expert Rev Anti Infect Ther. 2015;13:427-450. [PMID: 25724218 DOI: 10.1586/14787210.2015.1019867] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
488 Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. Clin Microbiol Infect 2015;21:969-74. [PMID: 26163104 DOI: 10.1016/j.cmi.2015.06.026] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
489 Sadeghi A, Shirvani-dastgerdi E, Tacke F, Yagmur E, Poortahmasebi V, Poorebrahim M, Mohraz M, Hajabdolbaghi M, Rasoolinejad M, Abbasian L, Jafari R, Fakhari Z, Norouzi M, Ebrahimian A, Geravand B, Alavian SM, Jazayeri SM. HBsAg mutations related to occult hepatitis B virus infection in HIV-positive patients result in a reduced secretion and conformational changes of HBsAg: HBsAg Related Mutations in Occult HBV Infection. J Med Virol 2017;89:246-56. [DOI: 10.1002/jmv.24623] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
490 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 12.1] [Reference Citation Analysis]
491 Taha SE, El-hady SA, Ahmed TM, Ahmed IZ. Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients with and without hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics 2013;14:353-60. [DOI: 10.1016/j.ejmhg.2013.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
492 Okamoto D, Nakayama H, Ikeda T, Ikeya S, Nagashima S, Takahashi M, Sugai Y, Okamoto H. Molecular analysis of the interspousal transmission of hepatitis B virus in two Japanese patients who acquired fulminant hepatitis B after 50 and 49 years of marriage. J Med Virol 2014;86:1851-60. [PMID: 25132075 DOI: 10.1002/jmv.24040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
493 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
494 Azarkar Z, Ziaee M, Ebrahimzadeh A, Sharifzadeh G, Javanmard D. Epidemiology, risk factors, and molecular characterization of occult hepatitis B infection among anti-hepatitis B core antigen alone subjects. J Med Virol 2019;91:615-22. [PMID: 30345529 DOI: 10.1002/jmv.25343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
495 Kim H, Kim BJ. Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants. Int J Mol Sci. 2015;16:13595-13609. [PMID: 26084041 DOI: 10.3390/ijms160613595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
496 Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68:313-321. [PMID: 29959168 DOI: 10.1136/gutjnl-2018-316490] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
497 Mirabet V, Álvarez M, Luis-Hidalgo M, Galán J, Puig N, Larrea L, Arbona C. Detection of hepatitis B virus in bone allografts from donors with occult hepatitis B infection. Cell Tissue Bank 2017;18:335-41. [PMID: 28748417 DOI: 10.1007/s10561-017-9644-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
498 Lin H, Zhao H, Tang X, Hu W, Jiang N, Zhu S, Huang C. Serological Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among Blood Donors. Hepat Mon 2016;16:e40492. [PMID: 27882070 DOI: 10.5812/hepatmon.40492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
499 Abu El Makarem MA, Abdel Hamid M, Abdel Aleem A, Ali A, Shatat M, Sayed D, Deaf A, Hamdy L, Tony EA. Prevalence of occult hepatitis B virus infection in hemodialysis patients from egypt with or without hepatitis C virus infection. Hepat Mon. 2012;12:253-258. [PMID: 22690232 DOI: 10.5812/hepatmon.665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
500 Zhang Z, Zhang L, Dai Y, Jin L, Sun B, Su Q, Li X. Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infection. J Med Virol. 2015;87:1890-1898. [PMID: 25964194 DOI: 10.1002/jmv.24245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
501 Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-puttini P, Galli M. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine 2017;84:525-30. [DOI: 10.1016/j.jbspin.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
502 Wang J, Liu Y, Liao H, Liu L, Chen R, Si L, Luo D, Huang B, Li L, Jiang J, Xu D. The sK122R mutation of hepatitis B virus (HBV) is associated with occult HBV infection: Analysis of a large cohort of Chinese patients. J Clin Virol 2020;130:104564. [PMID: 32763811 DOI: 10.1016/j.jcv.2020.104564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
503 Shire AM, Roberts LR. Occult hepatitis B virus infection: bit player or role player? Hepatology. 2011;54:760-763. [PMID: 21735471 DOI: 10.1002/hep.24528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
504 Candotti D, Allain JP. Molecular virology in transfusion medicine laboratory. Blood Transfus. 2013;11:203-216. [PMID: 23356973 DOI: 10.2450/2012.0219-12] [Cited by in F6Publishing: 5] [Reference Citation Analysis]